

**BEFORE THE
MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

**In the Matter of the First Amended
Accusation Against:**

Kareem Rashad Hubbard, M.D.

**Physician's and Surgeon's
Certificate No. A 128252**

Case No.: 800-2019-052153

Respondent.


DECISION

The attached Stipulated Settlement and Disciplinary Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.

This Decision shall become effective at 5:00 p.m. on March 3, 2023.

IT IS SO ORDERED: February 1, 2023.

MEDICAL BOARD OF CALIFORNIA



**Laurie Rose Lubiano, J.D., Chair
Panel A**

1 ROB BONTA
Attorney General of California
2 STEVE DIEHL
Supervising Deputy Attorney General
3 LYNNE K. DOMBROWSKI
Deputy Attorney General
4 State Bar No. 128080
455 Golden Gate Avenue, Suite 11000
5 San Francisco, CA 94102-7004
Telephone: (415) 510-3439
6 Facsimile: (415) 703-5480
E-mail: Lynne.Dombrowski@doj.ca.gov
7 *Attorneys for Complainant*

8
9 **BEFORE THE**
MEDICAL BOARD OF CALIFORNIA
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the First Amended Accusation
13 Against:

14 **KAREEM RASHAD HUBBARD, M.D.**
15 **13980 Blossom Hill Road**
Los Gatos, CA 95032-5121

16 **Physician's and Surgeon's Certificate**
17 **No. A 128252**

18 Respondent.

Case No. 800-2019-052153

STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER

19
20 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
21 entitled proceedings that the following matters are true:

22 **PARTIES**

23 1. William Prasifka (Complainant) is the Executive Director of the Medical Board of
24 California (Board). He brought this action solely in his official capacity and is represented in this
25 matter by Rob Bonta, Attorney General of the State of California, by Lynne K. Dombrowski,
26 Deputy Attorney General.

27 ///

28 ///

2. Respondent Kareem Rashad Hubbard, M.D. (Respondent) is represented in this proceeding by attorney John L. Fleeer, Esq., whose address is: 333 Benton St., Santa Rosa, CA 95401-4834; Email: jfleeerlaw@gmail.com .

3. On December 30, 2013, the Board issued Physician's and Surgeon's Certificate No. A 128252 to Kareem Rashad Hubbard, M.D. (Respondent). The Physician's and Surgeon's Certificate was in full force and effect at all times relevant to the charges brought in First Amended Accusation No. 800-2019-052153, and it will expire on September 30, 2023, unless renewed.

JURISDICTION

4. Accusation No. 800-2019-052153 was filed against Respondent and, along with all other statutorily required documents, was properly served on Respondent on January 6, 2022. Respondent timely filed his Notice of Defense contesting the Accusation. On May 27, 2022, the Board filed a First Amended Accusation 800-2019-052153, which is currently pending against Respondent.

5. A copy of First Amended Accusation No. 800-2019-052153 is attached as Exhibit A and is incorporated herein by reference.

ADVISEMENT AND WAIVERS

6. Respondent has carefully read, fully discussed with counsel, and understands the charges and allegations in First Amended Accusation No. 800-2019-052153. Respondent has also carefully read, fully discussed with his counsel, and understands the effects of this Stipulated Settlement and Disciplinary Order.

7. Respondent is fully aware of his legal rights in this matter, including the right to a hearing on the charges and allegations in the First Amended Accusation; the right to confront and cross-examine the witnesses against him; the right to present evidence and to testify on his own behalf; the right to the issuance of subpoenas to compel the attendance of witnesses and the production of documents; the right to reconsideration and court review of an adverse decision; and all other rights accorded by the California Administrative Procedure Act and other applicable laws.

8. Respondent voluntarily, knowingly, and intelligently waives and gives up each and every right set forth above.

CULPABILITY

9. Respondent admits the truth of each and every charge and allegation in First Amended Accusation No. 800-2019-052153.

10. Respondent agrees that his Physician's and Surgeon's Certificate is subject to discipline and he agrees to be bound by the Board's probationary terms as set forth in the Disciplinary Order below.

CONTINGENCY

11. This stipulation shall be subject to approval by the Medical Board of California. Respondent understands and agrees that counsel for Complainant and the staff of the Medical Board of California may communicate directly with the Board regarding this stipulation and settlement, without notice to or participation by Respondent or his counsel. By signing the stipulation, Respondent understands and agrees that he may not withdraw his agreement or seek to rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails to adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary Order shall be of no force or effect, except for this paragraph, it shall be inadmissible in any legal action between the parties, and the Board shall not be disqualified from further action by having considered this matter.

12. Respondent agrees that if he ever petitions for early termination or modification of probation, or if an accusation and/or petition to revoke probation is filed against him before the Board, all of the charges and allegations contained in First Amended Accusation No. 800-2019-052153 shall be deemed true, correct and fully admitted by respondent for purposes of any such proceeding or any other licensing proceeding involving Respondent in the State of California.

13. The parties understand and agree that Portable Document Format (PDF) and facsimile copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile signatures thereto, shall have the same force and effect as the originals.

1 14. In consideration of the foregoing admissions and stipulations, the parties agree that
2 the Board may, without further notice or opportunity to be heard by the Respondent, issue and
3 enter the following Disciplinary Order:

4 **DISCIPLINARY ORDER**

5 IT IS HEREBY ORDERED that Physician's and Surgeon's Certificate No. A 128252 issued
6 to Respondent Kareem Rashad Hubbard, M.D. is revoked. However, the revocation is stayed and
7 Respondent is placed on probation for four (4) years on the following terms and conditions:

8 1. **CONTROLLED SUBSTANCES - TOTAL RESTRICTION.** Respondent shall not
9 order, prescribe, dispense, administer, furnish, or possess any controlled substances as defined in
10 the California Uniform Controlled Substances Act.

11 Respondent shall not issue an oral or written recommendation or approval to a patient or a
12 patient's primary caregiver for the possession or cultivation of marijuana for the personal medical
13 purposes of the patient within the meaning of Health and Safety Code section 11362.5.

14 If Respondent forms the medical opinion, after an appropriate prior examination and a
15 medical indication, that a patient's medical condition may benefit from the use of marijuana,
16 Respondent shall so inform the patient and shall refer the patient to another physician who,
17 following an appropriate prior examination and a medical indication, may independently issue a
18 medically appropriate recommendation or approval for the possession or cultivation of marijuana
19 for the personal medical purposes of the patient within the meaning of Health and Safety Code
20 section 11362.5. In addition, Respondent shall inform the patient or the patient's primary
21 caregiver that Respondent is prohibited from issuing a recommendation or approval for the
22 possession or cultivation of marijuana for the personal medical purposes of the patient and that
23 the patient or the patient's primary caregiver may not rely on Respondent's statements to legally
24 possess or cultivate marijuana for the personal medical purposes of the patient. Respondent shall
25 fully document in the patient's chart that the patient or the patient's primary caregiver was so
26 informed. Nothing in this condition prohibits Respondent from providing the patient or the
27 patient's primary caregiver information about the possible medical benefits resulting from the use
28 of marijuana.

1 (a) CONDITION SUBSEQUENT: If the Board receives written notice from Respondent,
2 with documented proof, that (1) Respondent's DEA license has been reinstated in full and (2) that
3 Respondent has successfully completed a prescribing practices course, the Board will lift this
4 probation term of a total restriction of controlled substances and replace it with Optional
5 Probation Condition No. 8, for the duration of the probation, as follows:

6 CONTROLLED SUBSTANCES – MAINTAIN RECORDS AND ACCESS TO
7 RECORDS AND INVENTORIES: Respondent shall maintain a records of all controlled
8 substances ordered, prescribed, dispensed, administered, or possessed by Respondent, and any
9 recommendation or approval which enables a patient or patient's primary caregiver to possess or
10 cultivate marijuana for the personal medical purposes of the patient within the meaning of Health
11 and Safety Code section 11362.5, during probation, showing all of the following: 1) the name and
12 address of patient; 2) the date; 3) the character and quantity of controlled substances involved;
13 and 4) the indications and diagnosis for which the controlled substances were furnished.

14 Respondent shall keep these records in a separate file or ledger, in chronological order. All
15 records and any inventories of controlled substances shall be available for immediate inspection
16 and copying on the premises by the Board or its designee at all times during business hours and
17 shall be retained for the entire term of probation.

18 2. EDUCATION COURSE. Within 60 calendar days of the effective date of this
19 Decision, and on an annual basis thereafter, Respondent shall submit to the Board or its designee
20 for its prior approval educational program(s) or course(s) which shall not be less than 40 hours
21 per year, for each year of probation. The educational program(s) or course(s) shall be aimed at
22 correcting any areas of deficient practice or knowledge and shall be Category I certified. The
23 educational program(s) or course(s) shall be at Respondent's expense and shall be in addition to
24 the Continuing Medical Education (CME) requirements for renewal of licensure. Following the
25 completion of each course, the Board or its designee may administer an examination to test
26 Respondent's knowledge of the course. Respondent shall provide proof of attendance for 65
27 hours of CME of which 40 hours were in satisfaction of this condition.

28 ///

1 3. PREScribing PRACTICES COURSE. Within 60 calendar days of the effective
2 date of this Decision, Respondent shall enroll in a course in prescribing practices approved in
3 advance by the Board or its designee. Respondent shall provide the approved course provider
4 with any information and documents that the approved course provider may deem pertinent.
5 Respondent shall participate in and successfully complete the classroom component of the course
6 not later than six (6) months after Respondent's initial enrollment. Respondent shall successfully
7 complete any other component of the course within one (1) year of enrollment. The prescribing
8 practices course shall be at Respondent's expense and shall be in addition to the Continuing
9 Medical Education (CME) requirements for renewal of licensure.

10 A prescribing practices course taken after the acts that gave rise to the charges in the
11 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board
12 or its designee, be accepted towards the fulfillment of this condition if the course would have
13 been approved by the Board or its designee had the course been taken after the effective date of
14 this Decision.

15 Respondent shall submit a certification of successful completion to the Board or its
16 designee not later than 15 calendar days after successfully completing the course, or not later than
17 15 calendar days after the effective date of the Decision, whichever is later.

18 4. MEDICAL RECORD KEEPING COURSE. Within 60 calendar days of the effective
19 date of this Decision, Respondent shall enroll in a course in medical record keeping approved in
20 advance by the Board or its designee. Respondent shall provide the approved course provider
21 with any information and documents that the approved course provider may deem pertinent.
22 Respondent shall participate in and successfully complete the classroom component of the course
23 not later than six (6) months after Respondent's initial enrollment. Respondent shall successfully
24 complete any other component of the course within one (1) year of enrollment. The medical
25 record keeping course shall be at Respondent's expense and shall be in addition to the Continuing
26 Medical Education (CME) requirements for renewal of licensure.

27 A medical record keeping course taken after the acts that gave rise to the charges in the
28 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board

1 or its designee, be accepted towards the fulfillment of this condition if the course would have
2 been approved by the Board or its designee had the course been taken after the effective date of
3 this Decision.

4 Respondent shall submit a certification of successful completion to the Board or its
5 designee not later than 15 calendar days after successfully completing the course, or not later than
6 15 calendar days after the effective date of the Decision, whichever is later.

7 5. PROFESSIONALISM PROGRAM (ETHICS COURSE). Within 60 calendar days of
8 the effective date of this Decision, Respondent shall enroll in a professionalism program, that
9 meets the requirements of Title 16, California Code of Regulations (CCR) section 1358.1.
10 Respondent shall participate in and successfully complete that program. Respondent shall
11 provide any information and documents that the program may deem pertinent. Respondent shall
12 successfully complete the classroom component of the program not later than six (6) months after
13 Respondent's initial enrollment, and the longitudinal component of the program not later than the
14 time specified by the program, but no later than one (1) year after attending the classroom
15 component. The professionalism program shall be at Respondent's expense and shall be in
16 addition to the Continuing Medical Education (CME) requirements for renewal of licensure.

17 A professionalism program taken after the acts that gave rise to the charges in the
18 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board
19 or its designee, be accepted towards the fulfillment of this condition if the program would have
20 been approved by the Board or its designee had the program been taken after the effective date of
21 this Decision. Respondent shall submit a certification of successful completion to the Board or its
22 designee not later than 15 calendar days after successfully completing the program or not later
23 than 15 calendar days after the effective date of the Decision, whichever is later.

24 6. SOLO PRACTICE PROHIBITION. Respondent is prohibited from engaging in the
25 solo practice of medicine. Prohibited solo practice includes, but is not limited to, a practice
26 where: 1) Respondent merely shares office space with another physician but is not affiliated for
27 purposes of providing patient care, or 2) Respondent is the sole physician practitioner at that
28 location.

1 If Respondent fails to establish a practice with another physician or secure employment in
2 an appropriate practice setting within 60 calendar days of the effective date of this Decision,
3 Respondent shall receive a notification from the Board or its designee to cease the practice of
4 medicine within three (3) calendar days after being so notified. The Respondent shall not resume
5 practice until an appropriate practice setting is established.

6 If, during the course of the probation, the Respondent's practice setting changes and the
7 Respondent is no longer practicing in a setting in compliance with this Decision, the Respondent
8 shall notify the Board or its designee within five (5) calendar days of the practice setting change.

9 If Respondent fails to establish a practice with another physician or secure employment in an
10 appropriate practice setting within 60 calendar days of the practice setting change, Respondent
11 shall receive a notification from the Board or its designee to cease the practice of medicine within
12 three (3) calendar days after being so notified. The Respondent shall not resume practice until an
13 appropriate practice setting is established.

14 7. NOTIFICATION. Within seven (7) days of the effective date of this Decision, the
15 Respondent shall provide a true copy of this Decision and Accusation to the Chief of Staff or the
16 Chief Executive Officer at every hospital where privileges or membership are extended to
17 Respondent, at any other facility where Respondent engages in the practice of medicine,
18 including all physician and locum tenens registries or other similar agencies, and to the Chief
19 Executive Officer at every insurance carrier which extends malpractice insurance coverage to
20 Respondent. Respondent shall submit proof of compliance to the Board or its designee within 15
21 calendar days. This condition shall apply to any change(s) in hospitals, other facilities or
22 insurance carrier.

23 8. SUPERVISION OF PHYSICIAN ASSISTANTS AND ADVANCED PRACTICE
24 NURSES. During probation, Respondent is prohibited from supervising physician assistants and
25 advanced practice nurses.

26 9. OBEY ALL LAWS. Respondent shall obey all federal, state and local laws, all rules
27 governing the practice of medicine in California and remain in full compliance with any court
28 ordered criminal probation, payments, and other orders.

1 10. INVESTIGATION/ENFORCEMENT COST RECOVERY. Respondent is hereby
2 ordered to reimburse the Board its costs of investigation and enforcement, including, but not
3 limited to, expert review, amended accusations, legal reviews, investigation(s), and subpoena
4 enforcement, as applicable, in the amount of \$13,240 (thirteen thousand two hundred forty
5 dollars). Costs shall be payable to the Medical Board of California. Failure to pay such costs
6 shall be considered a violation of probation.

7 Payment must be made in full within 30 calendar days of the effective date of the Order, or
8 by a payment plan approved by the Medical Board of California. Any and all requests for a
9 payment plan shall be submitted in writing by Respondent to the Board. Failure to comply with
10 the payment plan shall be considered a violation of probation.

11 The filing of bankruptcy by Respondent shall not relieve respondent of the responsibility to
12 repay investigation and enforcement costs, including expert review costs (if applicable).

13 11. QUARTERLY DECLARATIONS. Respondent shall submit quarterly declarations
14 under penalty of perjury on forms provided by the Board, stating whether there has been
15 compliance with all the conditions of probation. Respondent shall submit quarterly declarations
16 not later than 10 calendar days after the end of the preceding quarter.

17 12. GENERAL PROBATION REQUIREMENTS.

18 Compliance with Probation Unit

19 Respondent shall comply with the Board's probation unit.

20 Address Changes

21 Respondent shall, at all times, keep the Board informed of Respondent's business and
22 residence addresses, email address (if available), and telephone number. Changes of such
23 addresses shall be immediately communicated in writing to the Board or its designee. Under no
24 circumstances shall a post office box serve as an address of record, except as allowed by Business
25 and Professions Code section 2021, subdivision (b).

26 ///

27 ///

28 ///

1 Place of Practice

2 Respondent shall not engage in the practice of medicine in Respondent's or patient's place
3 of residence, unless the patient resides in a skilled nursing facility or other similar licensed
4 facility.

5 License Renewal

6 Respondent shall maintain a current and renewed California physician's and surgeon's
7 license.

8 Travel or Residence Outside California

9 Respondent shall immediately inform the Board or its designee, in writing, of travel to any
10 areas outside the jurisdiction of California which lasts, or is contemplated to last, more than thirty
11 (30) calendar days.

12 In the event Respondent should leave the State of California to reside or to practice
13 Respondent shall notify the Board or its designee in writing 30 calendar days prior to the dates of
14 departure and return.

15 13. INTERVIEW WITH THE BOARD OR ITS DESIGNEE. Respondent shall be
16 available in person upon request for interviews either at Respondent's place of business or at the
17 probation unit office, with or without prior notice throughout the term of probation.

18 14. NON-PRACTICE WHILE ON PROBATION. Respondent shall notify the Board or
19 its designee in writing within 15 calendar days of any periods of non-practice lasting more than
20 30 calendar days and within 15 calendar days of Respondent's return to practice. Non-practice is
21 defined as any period of time Respondent is not practicing medicine as defined in Business and
22 Professions Code sections 2051 and 2052 for at least 40 hours in a calendar month in direct
23 patient care, clinical activity or teaching, or other activity as approved by the Board. If
24 Respondent resides in California and is considered to be in non-practice, Respondent shall
25 comply with all terms and conditions of probation. All time spent in an intensive training
26 program which has been approved by the Board or its designee shall not be considered non-
27 practice and does not relieve Respondent from complying with all the terms and conditions of
28 probation. Practicing medicine in another state of the United States or Federal jurisdiction while

1 on probation with the medical licensing authority of that state or jurisdiction shall not be
2 considered non-practice. A Board-ordered suspension of practice shall not be considered as a
3 period of non-practice.

4 In the event Respondent's period of non-practice while on probation exceeds 18 calendar
5 months, Respondent shall successfully complete the Federation of State Medical Boards's Special
6 Purpose Examination, or, at the Board's discretion, a clinical competence assessment program
7 that meets the criteria of Condition 18 of the current version of the Board's "Manual of Model
8 Disciplinary Orders and Disciplinary Guidelines" prior to resuming the practice of medicine.

9 Respondent's period of non-practice while on probation shall not exceed two (2) years.

10 Periods of non-practice will not apply to the reduction of the probationary term.

11 Periods of non-practice for a Respondent residing outside of California will relieve
12 Respondent of the responsibility to comply with the probationary terms and conditions with the
13 exception of this condition and the following terms and conditions of probation: Obey All Laws;
14 General Probation Requirements; Quarterly Declarations; Abstain from the Use of Alcohol and/or
15 Controlled Substances; and Biological Fluid Testing..

16 15. COMPLETION OF PROBATION. Respondent shall comply with all financial
17 obligations (e.g., restitution, probation costs) not later than 120 calendar days prior to the
18 completion of probation. This term does not include cost recovery, which is due within 30
19 calendar days of the effective date of the Order, or by a payment plan approved by the Medical
20 Board and timely satisfied. Upon successful completion of probation, Respondent's certificate
21 shall be fully restored.

22 16. VIOLATION OF PROBATION. Failure to fully comply with any term or condition
23 of probation is a violation of probation. If Respondent violates probation in any respect, the
24 Board, after giving Respondent notice and the opportunity to be heard, may revoke probation and
25 carry out the disciplinary order that was stayed. If an Accusation, or Petition to Revoke Probation,
26 or an Interim Suspension Order is filed against Respondent during probation, the Board shall have
27 continuing jurisdiction until the matter is final, and the period of probation shall be extended until
28 the matter is final.

1 17. LICENSE SURRENDER. Following the effective date of this Decision, if
2 Respondent ceases practicing due to retirement or health reasons or is otherwise unable to satisfy
3 the terms and conditions of probation, Respondent may request to surrender his or her license.
4 The Board reserves the right to evaluate Respondent's request and to exercise its discretion in
5 determining whether or not to grant the request, or to take any other action deemed appropriate
6 and reasonable under the circumstances. Upon formal acceptance of the surrender, Respondent
7 shall within 15 calendar days deliver Respondent's wallet and wall certificate to the Board or its
8 designee and Respondent shall no longer practice medicine. Respondent will no longer be subject
9 to the terms and conditions of probation. If Respondent re-applies for a medical license, the
10 application shall be treated as a petition for reinstatement of a revoked certificate.

11 18. PROBATION MONITORING COSTS. Respondent shall pay the costs associated
12 with probation monitoring each and every year of probation, as designated by the Board, which
13 may be adjusted on an annual basis. Such costs shall be payable to the Medical Board of
14 California and delivered to the Board or its designee no later than January 31 of each calendar
15 year.

16 19. FUTURE ADMISSIONS CLAUSE. If Respondent should ever apply or reapply for
17 a new license or certification, or petition for reinstatement of a license, by any other health care
18 licensing action agency in the State of California, all of the charges and allegations contained in
19 First Amended Accusation No. 800-2019-052153 shall be deemed to be true, correct, and
20 admitted by Respondent for the purpose of any Statement of Issues or any other proceeding
21 seeking to deny or restrict license.

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///

1 ACCEPTANCE

2 I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully
3 discussed it with my attorney, John L. Fleer. I understand the stipulation and the effect it will
4 have on my Physician's and Surgeon's Certificate. I enter into this Stipulated Settlement and
5 Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the
6 Decision and Order of the Medical Board of California.

7
8 DATED: 9-23-2022

K. Hubbard MD
KAREEM RASHAD HUBBARD, M.D.
Respondent

10
11
12
13
14 I have read and fully discussed with Respondent Kareem Rashad Hubbard, M.D. the terms
15 and conditions and other matters contained in the above Stipulated Settlement and Disciplinary
16 Order. I approve its form and content.

17
18 DATED: 9-23-22

John L. Fleer
JOHN L. FLEER
Attorney for Respondent

ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Medical Board of California.

DATED: 10/14/2022

Respectfully submitted,

ROB BONTA
Attorney General of California
STEVE DIEHL
Supervising Deputy Attorney General

Lynne K. Dombrowski
LYNNE K. DOMBROWSKI
Deputy Attorney General
Attorneys for Complainant

SF2021402477

Exhibit A

First Amended Accusation No. 800-2019-052153

1 ROB BONTA
Attorney General of California
2 JANE ZACK SIMON
Supervising Deputy Attorney General
3 ANA GONZALEZ
Deputy Attorney General
4 State Bar No. 190263
455 Golden Gate Avenue, Suite 11000
5 San Francisco, CA 94102-7004
Telephone: (415) 510-3608
6 Facsimile: (415) 703-5480
E-mail: Ana.Gonzalez@doj.ca.gov
7 Attorneys for Complainant

8
9 **BEFORE THE**
MEDICAL BOARD OF CALIFORNIA
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the First Amended Accusation
13 Against:

Case No. 800-2019-052153

FIRST AMENDED ACCUSATION

14 **KAREEM RASHAD HUBBARD, M.D.**
13980 Blossom Hill Road
15 Los Gatos, CA 95032-5121

16 Physician's and Surgeon's Certificate
No. A 128252,

17 Respondent.
18

19 **PARTIES**

20 1. William Prasifka (Complainant) brings this First Amended Accusation solely in his
21 official capacity as the Executive Director of the Medical Board of California, Department of
22 Consumer Affairs (Board).

23 2. On December 30, 2013, the Board issued Physician's and Surgeon's Certificate
24 Number A 128252 to Kareem Rashad Hubbard, M.D. (Respondent). The Physician's and
25 Surgeon's Certificate was in full force and effect at all times relevant to the charges brought
26 herein and will expire on September 30, 2023, unless renewed.

27 ///

JURISDICTION

3. This First Amended Accusation is brought before the Board, under the authority of the following laws. All section references are to the Business and Professions Code (Code) unless otherwise indicated.

4. Section 2227 of the Code provides that a licensee who is found guilty under the Medical Practice Act may have his or her license revoked, suspended for a period not to exceed one year, placed on probation and required to pay the costs of probation monitoring, or such other action taken in relation to discipline as the Board deems proper.

5. Section 2234 of the Code, states:

The board shall take action against any licensee who is charged with unprofessional conduct. In addition to other provisions of this article, unprofessional conduct includes, but is not limited to, the following:

(a) Violating or attempting to violate, directly or indirectly, assisting in or abetting the violation of, or conspiring to violate any provision of this chapter.

(b) Gross negligence.

(c) Repeated negligent acts. To be repeated, there must be two or more negligent acts or omissions. An initial negligent act or omission followed by a separate and distinct departure from the applicable standard of care shall constitute repeated negligent acts.

(e) The commission of any act involving dishonesty or corruption that is substantially related to the qualifications, functions, or duties of a physician and surgeon.

(f) Any action or conduct that would have warranted the denial of a certificate.

6. Section 2238 of the Code states:

A violation of any federal statute or federal regulation or any of the statutes or regulations of this state regulating dangerous drugs or controlled substances constitutes unprofessional conduct.

7. Section 2261 of the Code states:

Knowingly making or signing any certificate or other document directly or indirectly related to the practice of medicine or podiatry which falsely represents the existence or nonexistence of a state of facts, constitutes unprofessional conduct.

8. Section 141 of the Code states:

(a) For any licensee holding a license issued by a board under the jurisdiction of

1 the department, a disciplinary action taken by another state, by any agency of the
2 federal government, or by another country for any act substantially related to the
3 practice regulated by the California license, may be a ground for disciplinary action
4 by the respective state licensing board. A certified copy of the record of the
disciplinary action taken against the licensee by another state, an agency of the
federal government, or another country shall be conclusive evidence of the events
related therein.

5 (b) Nothing in this section shall preclude a board from applying a specific
6 statutory provision in the licensing act administered by that board that provides for
discipline based upon a disciplinary action taken against the licensee by another state,
an agency of the federal government, or another country.

7 9. Section 2266 of the Code states: The failure of a physician and surgeon to maintain
8 adequate and accurate records relating to the provision of services to their patients constitutes
9 unprofessional conduct.

10 10. Section 2228.1 of the Code states in part:

11 (a) On and after July 1, 2019, except as otherwise provided in subdivision (c),
12 the board shall require a licensee to provide a separate disclosure that includes the
13 licensee's probation status, the length of the probation, the probation end date, all
14 practice restrictions placed on the licensee by the board, the board's telephone
15 number, and an explanation of how the patient can find further information on the
16 licensee's probation on the licensee's profile page on the board's online license
information Internet Web site, to a patient or the patient's guardian or health care
surrogate before the patient's first visit following the probationary order while the
licensee is on probation pursuant to a probationary order made on and after July 1,
2019, in any of the following circumstances:

17 (1) A final adjudication by the board following an administrative hearing or
18 admitted findings or prima facie showing in a stipulated settlement establishing any
of the following:

19 ...

20 (D) Inappropriate prescribing resulting in harm to patients and a probationary
period of five years or more.

21 (2) An accusation or statement of issues alleged that the licensee committed any
22 of the acts described in subparagraphs (A) to (D), inclusive, of paragraph (1), and a
stipulated settlement based upon a nolo contendere or other similar compromise that
23 does not include any prima facie showing or admission of guilt or fact but does
include an express acknowledgment that the disclosure requirements of this section
24 would serve to protect the public interest.

25 (b) A licensee required to provide a disclosure pursuant to subdivision (a) shall
26 obtain from the patient, or the patient's guardian or health care surrogate, a separate,
signed copy of that disclosure.

27 (c) A licensee shall not be required to provide a disclosure pursuant to
subdivision (a) if any of the following applies:

28 (1) The patient is unconscious or otherwise unable to comprehend the

1 disclosure and sign the copy of the disclosure pursuant to subdivision (b) and a
2 guardian or health care surrogate is unavailable to comprehend the disclosure and
3 sign the copy.

4 (2) The visit occurs in an emergency room or an urgent care facility or the visit
5 is unscheduled, including consultations in inpatient facilities.

6 (3) The licensee who will be treating the patient during the visit is not known to
7 the patient until immediately prior to the start of the visit.

8 (4) The licensee does not have a direct treatment relationship with the patient.

9 (d) On and after July 1, 2019, the board shall provide the following
10 information, with respect to licensees on probation and licensees practicing under
11 probationary licenses, in plain view on the licensee's profile page on the board's
12 online license information Internet Web site.

13 (1) For probation imposed pursuant to a stipulated settlement, the causes
14 alleged in the operative accusation along with a designation identifying those causes
15 by which the licensee has expressly admitted guilt and a statement that acceptance of
16 the settlement is not an admission of guilt.

17 (2) For probation imposed by an adjudicated decision of the board, the causes
18 for probation stated in the final probationary order.

19 (3) For a licensee granted a probationary license, the causes by which the
20 probationary license was imposed.

21 (4) The length of the probation and end date.

22 (5) All practice restrictions placed on the license by the board.

23 (e) Section 2314 shall not apply to this section.

24 COST RECOVERY

25 11. Section 125.3 of the Code states:

26 (a) Except as otherwise provided by law, in any order issued in resolution of a
27 disciplinary proceeding before any board within the department or before the
28 Osteopathic Medical Board, upon request of the entity bringing the proceeding, the
administrative law judge may direct a licensee found to have committed a violation or
violations of the licensing act to pay a sum not to exceed the reasonable costs of the
investigation and enforcement of the case.

(b) In the case of a disciplined licensee that is a corporation or a partnership, the
order may be made against the licensed corporate entity or licensed partnership.

(c) A certified copy of the actual costs, or a good faith estimate of costs where
actual costs are not available, signed by the entity bringing the proceeding or its
designated representative shall be prima facie evidence of reasonable costs of
investigation and prosecution of the case. The costs shall include the amount of
investigative and enforcement costs up to the date of the hearing, including, but not
limited to, charges imposed by the Attorney General.

(d) The administrative law judge shall make a proposed finding of the amount

1 of reasonable costs of investigation and prosecution of the case when requested
2 pursuant to subdivision (a). The finding of the administrative law judge with regard to
3 costs shall not be reviewable by the board to increase the cost award. The board may
4 reduce or eliminate the cost award, or remand to the administrative law judge if the
5 proposed decision fails to make a finding on costs requested pursuant to subdivision
6 (a).

7 (e) If an order for recovery of costs is made and timely payment is not made as
8 directed in the board's decision, the board may enforce the order for repayment in any
9 appropriate court. This right of enforcement shall be in addition to any other rights
10 the board may have as to any licensee to pay costs.

11 (f) In any action for recovery of costs, proof of the board's decision shall be
12 conclusive proof of the validity of the order of payment and the terms for payment.

13 (g) (1) Except as provided in paragraph (2), the board shall not renew or
14 reinstate the license of any licensee who has failed to pay all of the costs ordered
15 under this section.

16 (2) Notwithstanding paragraph (1), the board may, in its discretion,
17 conditionally renew or reinstate for a maximum of one year the license of any
18 licensee who demonstrates financial hardship and who enters into a formal agreement
19 with the board to reimburse the board within that one-year period for the unpaid
20 costs.

21 (h) All costs recovered under this section shall be considered a reimbursement
22 for costs incurred and shall be deposited in the fund of the board recovering the costs
23 to be available upon appropriation by the Legislature.

24 (i) Nothing in this section shall preclude a board from including the recovery of
25 the costs of investigation and enforcement of a case in any stipulated settlement.

26 (j) This section does not apply to any board if a specific statutory provision in
27 that board's licensing act provides for recovery of costs in an administrative
28 disciplinary proceeding.

DEFINITIONS

29 12. Carisoprodol (trade name Soma) is a muscle-relaxant and sedative. It is a dangerous
30 drug as defined in section 4022 of the Business and Professions Code, and a schedule IV
31 controlled substance as defined by section 11057 of the Health and Safety Code. Since the effects
32 of carisoprodol and alcohol or carisoprodol and other central nervous system depressants or
33 psychotropic drugs may be additive, appropriate caution should be exercised with patients who
34 take more than one of these agents simultaneously. Carisoprodol is metabolized in the liver and
35 excreted by the kidneys; to avoid its excess accumulation, caution should be exercised in
36 administration to patients with compromised liver or kidney functions.

1 13. Clonazepam (trade name Klonopin) is an anticonvulsant of the benzodiazepine class
2 of drugs. It is a dangerous drug as defined in section 4022 of the Business and Professions Code
3 and a Schedule IV controlled substance as defined by section 11057 of the Health and Safety
4 Code. It produces central nervous system depression and should be used with caution with other
5 central nervous system depressant drugs. Like other benzodiazepines, it can produce
6 psychological and physical dependence. Withdrawal symptoms similar to those noted with
7 barbiturates and alcohol have been noted upon abrupt discontinuance. The initial dosage for
8 adults should not exceed 1.5 mg per day divided in three doses.

9 14. Dextroamphetamine sulphate (trade name Adderall) is mixed salts of a single-entity
10 amphetamine product. Is considered a dangerous drug as defined in section 4022 of the Business
11 and Professions Code and a schedule II controlled substance as defined by section 11055 of the
12 Health and Safety Code. Adderall is indicated for Attention Deficit Disorder with Hyperactivity
13 and Narcolepsy. It is contraindicated for patients with advanced arteriosclerosis, symptomatic
14 cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known
15 hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma, agitated states, a
16 history of drug abuse, and patients who have taken monoamine oxidase inhibitors during or
17 within 14 days of administration. Administration of amphetamine to psychotic children may
18 exacerbate symptoms of behavior disturbance and thought disorder. Caution is to be exercised in
19 prescribing amphetamines for patients with even mild hypertension. The least amount feasible
20 should be prescribed or dispensed at one time in order to minimize the possibility of overdose.
21 Amphetamines have been extensively abused. Tolerance, extreme psychological dependence,
22 and severe social disability have occurred. There are reports of patients who have increased the
23 dosage to many times that recommended. For Deficit Disorder with hyperactivity, only in rare
24 cases will it be necessary to exceed a total of 40 mg per day. For narcolepsy, the usual dose is 5
25 mg to 60 mg per day in divided doses depending on individual patient response

26 15. Fentanyl (trade name Duragesic, Fentora) is an opioid analgesic. Fentanyl is a
27 dangerous drug as defined in section 4022 of the Business and Professions Code and a schedule II
28 controlled substance as defined by section 11055 of the Health and Safety Code. Duragesic is a

1 strong opioid medication and is indicated only for treatment of chronic pain (such as that of
2 malignancy) that cannot be managed by lesser means and requires continuous opioid
3 administration. Duragesic presents a risk of serious or life-threatening hypoventilation. When
4 patients are receiving Duragesic, the dosage of central nervous system depressant drugs should be
5 reduced at least 50%. Use of Duragesic together with other central nervous system depressants,
6 including alcohol, can result in increased risk to the patient. It should be used with caution in
7 individuals with a history of alcohol or drug abuse, particularly if they are outside of a medically
8 controlled environment. Duragesic can produce drug dependence similar to that produced by
9 morphine and has the potential for abuse. It is physically and psychologically addictive.
10 Duragesic patches are available in 25 mcg/hour, 50 mcg/hour, 75 mcg/hour and 100 mcg/hour.
11 Patches over 25 mcg/hour should only be used in opioid tolerant patients. Duragesic-100 patches
12 contain 10 mg fentanyl and provide analgesic effects approximately equivalent to 315-404 mg of
13 oral morphine per day. Since there has been no systematic evaluation of Duragesic as an initial
14 opioid analgesic in the management of chronic pain, the lowest dosage, 25 mcg per hour, should
15 be used as the initial dose for chronic pain.

16 16. Hydrocodone with acetaminophen (trade names such as Zohydro ER, Vicodin, Norco
17 or Lortab, also known as hydrocodone w/APAP (acetaminophen)) is a semi-synthetic narcotic
18 analgesic, a dangerous drug as defined in section 4022 of the Business and Professions Code, and
19 a Schedule II controlled substance and narcotic as defined by section 11055, subdivision (e) of
20 the Health and Safety Code. Repeated administration of hydrocodone over a course of several
21 weeks may result in psychic and physical dependence. The usual adult dosage is one tablet every
22 four to six hours as needed for pain. The total 24-hour dose should not exceed 6 tablets.

23 17. Hydromorphone (trade name Dilaudid) is a dangerous drug as defined in section 4022
24 of the Business and Professions Code, and a Schedule II controlled substance as defined by
25 section 11055, subdivision (d) of the Health and Safety Code. Dilaudid is a hydrogenated ketone
26 of morphine and is a narcotic analgesic. Its principal therapeutic use is relief of pain. Psychic
27 dependence, physical dependence, and tolerance may develop upon repeated administration of
28 narcotics; therefore, it should be prescribed and administered with caution. Physical dependence,

1 the condition in which continued administration of the drug is required to prevent the appearance
2 of a withdrawal syndrome, usually assumes clinically significant proportions after several weeks
3 of continued use. Side effects include drowsiness, mental clouding, respiratory depression, and
4 vomiting. The usual starting dosage for injections is 1-2 mg. The usual oral dose is 2 mg every
5 two to four hours as necessary. Patients receiving other narcotic analgesics, anesthetics,
6 phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants and other central
7 nervous system depressants, including alcohol, may exhibit an additive central nervous system
8 depression. When such combined therapy is contemplated, the use of one or both agents should
9 be reduced.

10 18. Levorphanol (trade name Levo-Dromoran) is an opioid medicine that is used to treat
11 moderate to severe pain. It is a dangerous drug as defined in section 4022 of the Business and
12 Professions Code and a schedule II controlled substance and narcotic as defined by section 11055,
13 subdivision (c) of the Health and Safety Code. Levorphanol has a high risk of addiction, abuse,
14 and misuse. Levorphanol is 4 to 8 times as potent as morphine and has a longer half-life. As a
15 opioid analgesic the initial dose is typically 1 to 2 mg orally every 6 to 8 hours as needed for pain.

16 19. Methadone hydrochloride (trade names Methadose and Dolophine) is a synthetic
17 narcotic analgesic with multiple actions quantitatively similar to those of morphine. It is a
18 dangerous drug as defined in section 4022 of the Business and Professions Code and a schedule II
19 controlled substance and narcotic as defined by section 11055, subdivision (c) of the Health and
20 Safety Code. Methadone can produce drug dependence of the morphine type and, therefore, has
21 the potential for being abused. Psychic dependence, physical dependence, and tolerance may
22 develop upon repeated administration of methadone, and it should be prescribed and administered
23 with the same degree of caution appropriate to the use of morphine. Methadone should be used
24 with caution and in reduced dosage in patients who are concurrently receiving other narcotic
25 analgesics. The usual adult dosage is 2.5 mg. to 10 mg. every three to four hours as necessary for
26 severe acute pain.

27 20. Morphine is for use in patients who require a potent opioid analgesic for relief of
28 moderate to severe pain. Morphine is a Schedule II controlled substance and narcotic as defined

1 by section 11055, subdivision (b)(1) of the Health and Safety Code and a dangerous drug as
2 defined in section 4022 of the Business and Professions Code. Morphine can produce drug
3 dependence and has a potential for being abused. Tolerance and psychological and physical
4 dependence may develop upon repeated administration. Abrupt cessation or a sudden reduction
5 in dose after prolonged use may result in withdrawal symptoms. After prolonged exposure to
6 morphine, if withdrawal is necessary, it must be undertaken gradually.

7 21. Oxycodone with acetaminophen and oxycodone with aspirin both contain oxycodone
8 (trade name Oxycontin) a white odorless crystalline powder derived from the opium alkaloid,
9 thebaine. Oxycodone is a semisynthetic narcotic analgesic with multiple actions qualitatively
10 similar to those of morphine. It is a dangerous drug as defined in section 4022 of the Business
11 and Professions Code and a schedule II controlled substance and narcotic as defined by section
12 11055, subdivision (b)(1) of the Health and Safety Code. Oxycodone can produce drug
13 dependence of the morphine type and, therefore, has the potential for being abused

14 22. Tapentadol (trade name Nucynta) is an opioid agonist. Nucynta is a Schedule II
15 controlled substance and narcotic as defined by section 11055, subdivision (b)(1) of the Health
16 and Safety Code and a dangerous drug as defined in section 4022 of the Business and Professions
17 Code. Nucynta use is associated with a significant potential for overdose or poisoning; proper
18 patient selection and counseling is recommended. The extended-release formulation is not
19 intended for use in the management of acute pain or on an as-needed basis; it is intended only for
20 patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

21 23. Zolpidem (trade name Ambien) is a non-benzodiazepine hypnotic of the
22 imidazopyridine class. It is a dangerous drug as defined in section 4022 of the Business and
23 Professions Code, and a Schedule IV controlled substance as defined by section 11057 of the
24 Health and Safety Code. It is indicated for the short-term treatment of insomnia. It is a central
25 nervous system depressant and should be used cautiously in combination with other central
26 nervous system depressants. Any central nervous system depressant could potentially enhance
27 the central nervous system depressive effects of Ambien. It should be administered cautiously to
28 patients exhibiting signs or symptoms of depression because of the risk of suicide. Because of the

1 risk of habituation and dependence, individuals with a history of addiction to or abuse of drugs or
2 alcohol should be carefully monitored while receiving Ambien. The recommended dosage for
3 adults is 10 mg immediately before bedtime.

4
5 **FIRST CAUSE FOR DISCIPLINE**

6 **(Unprofessional Conduct; and/or Gross Negligence and/or Repeated Negligent Acts; and/or
7 Inadequate Medical Record Keeping in the Care Provided to Patient 1, MH)¹**

8 24. Respondent Kareem Rashad Hubbard, M.D. is subject to disciplinary action under
9 sections 2234, 2234(b), 2234(c); and/or 2266 of the Code, regarding his treatment of Patient 1.
10 The circumstances are as follows:

11 25. Based on the available records, Respondent began treating Patient 1 on February 13,
12 2017. Patient 1's diagnosis included chronic migraine, cervicalgia, other cervical disc
13 degeneration and then post-laminectomy syndrome. Respondent began prescribing Patient 1's
14 pain medications on May 9, 2017. Over the course of treatment Respondent's prescriptions
15 included methadone, hydromorphone, morphine, and fentanyl.

16 26. Multiple inconsistent urine drug tests (UDT) appeared in Patient 1's chart. The
17 Controlled Substance Utilization Review and Evaluation System (CURES)² shows that on August
18 17, 2017, Patient 1 was prescribed a thirty-day supply of hydromorphone in tab and liquid form.
19 The UDT dated September 15, 2017, for this patient was negative for hydromorphone and
20 positive for methadone.

21 27. On November 10, 2017, Patient 1 signed a "Pain Treatment with Opioid Medications:
22 Patient Agreement" for her treatment with Respondent, which stated the patient would take no
23 drugs other than those prescribed, would take the drugs as prescribed, would be subject to urine
24 testing, and may no longer be treated in the office if any of part of the agreement was broken.

25
26 ¹ Names are redacted to protect privacy interests. Respondent knows the names of the
27 patients and can confirm identities through discovery.

28 ² CURES (Controlled Substance Utilization Review and Evaluation System) is a database
of Schedule II, III and IV controlled substance prescriptions dispensed in California serving the
public health, regulatory oversight agencies and law enforcement.

1 28. CURES shows that on December 2, 2017, Patient 1 was prescribed a thirty-day
2 supply of hydromorphone in tab and liquid form. The UDT for this patient from January 3, 2018,
3 was negative for hydromorphone.

4 29. CURES shows a thirty-day supply of hydromorphone in tab form was prescribed to
5 Patient 1 on February 8, 2018. The patient's March 30, 2018, UDT was negative for
6 hydromorphone.

7 30. CURES shows a thirty-day supply of hydromorphone tabs was prescribed to Patient 1
8 on May 4, 2018. Records show the June 6, 2018, UDT for Patient 1 was negative for
9 hydromorphone.

10 31. CURES shows Patient 1 was prescribed a thirty-day supply of hydromorphone tabs
11 on August 3, 2018, a thirty-day supply of liquid form morphine on July 5, 2018 and July 27,
12 2018, and another 15-day supply of liquid form morphine on August 13, 2018. Patient 1's
13 August 30, 2018, UDT was negative for morphine and negative for hydromorphone.

14 32. On August 30, 2018, Respondent documented in the medical chart that Patient 1 was
15 pregnant.

16 33. Patient 1's morphine prescription was increased while she was pregnant. On July 5,
17 2018 and July 7, 2018, Respondent prescribed Patient 1 a 30-day supply of morphine (quantity:
18 50 of 25 mg/ 1 ml). From August 13, 2018 through October 29, 2018, on six occasions,
19 Respondent prescribed the same quantity (quantity: 50 of 25 mg/ 1) but at a shortened 15-day
20 supply. On November 21, 2018, Respondent prescribed the same quantity (quantity: 50 of 25
21 mg/ 1 ml) but as a 10-day supply.

22 34. From August 2018 through November 2018, Patient 1 was also being prescribed
23 methadone (10 mg tab, every 6 hours for a 30-day supply) and hydromorphone (8 mg tab,
24 maximum 6 tabs a day for a 30-day supply) while pregnant.

25 35. On January 23, 2019, Patient 1 was admitted to the hospital, diagnosed with long
26 term opiate use and pre-existing hypertension with childbirth, and discharged on January 30,
27 2019.

28

36. Respondent's overall care and treatment of Patient 1 constitutes unprofessional conduct through gross negligence and/or repeated negligent acts and/or failure to maintain adequate and accurate medical records for reasons including, but not limited, to the following:

a. Respondent did not address, and/or document addressing, the multiple inconsistent UDTs and/or a meaningful and adequate substance abuse history over the course of treatment;

b. Respondent's management of Patient 1's migraine symptoms with overuse of prescription controlled substances could have exacerbated symptoms by turning episodic symptoms to chronic symptoms with rebound drug induced headaches; and

c. Respondent failed to taper the opioids during Patient 1's pregnancy to the lowest effective dose and/or failed to document why the risks of the prescribing regimen were outweighed by the potential benefits.

SECOND CAUSE FOR DISCIPLINE

(Unprofessional Conduct; and/or Repeated Negligent Acts; and/or Inadequate Medical Record Keeping in the Care Provided to Patient 2, CW)

37. Respondent Kareem Rashad Hubbard, M.D. is subject to disciplinary action under sections 2234, 2234(c); and/or 2266 of the Code, regarding his treatment of Patient 2. The circumstances are as follows:

38. On an initial evaluation in the clinic on January 31, 2017, Respondent diagnosed Patient 2 with cervicalgia, cervical radiculopathy, thoracic spine pain, low back pain, sleep disorder, and lumbar radiculopathy. The diagnosis of long term current use of opioids was added on July 26, 2017. Patient 2 signed a medication agreement with the office on January 31, 2017, and another one on October 28, 2017. Respondent took over the medication management of this patient on April 27, 2017. During the course of treatment Respondent prescribed the following drugs: hydromorphone, hydrocodone, fentanyl, zolpidem, morphine, and levorphanol.

39. The March 28, 2017, UDT for Patient 2 was positive for the opioid agonist tapentadol (trade name Nucynta), when there was no prescription filled for Nucynta from September 23, 2016 through March 28, 2017.

1 40. The March 28, 2017, UDT was negative for zolpidem when Respondent had
2 prescribed Patient 2 a 30-day supply of zolpidem on March 9, 2017.

3 41. Respondent's overall care and treatment of Patient 2 constitutes unprofessional
4 conduct through repeated negligent acts and/or failure to maintain adequate and accurate medical
5 records for reasons including, but not limited, to the following:

6 a. Respondent did not address, and/or document addressing, the inconsistent UDTs,

7
8 **THIRD CAUSE FOR DISCIPLINE**

9 **(Unprofessional Conduct; and/or Repeated Negligent Acts; and/or Inadequate Medical
Record Keeping in the Care Provided to Patient 3, SS)**

10 42. Respondent Kareem Rashad Hubbard, M.D. is subject to disciplinary action under
11 sections 2234, 2234(c); and/or 2266 of the Code, regarding his treatment of Patient 3. The
12 circumstances are as follows:

13 43. Patient 3 was initially evaluated by Respondent on February 6, 2017, for abdominal
14 and pelvic pain, and was diagnosed with acute pancreatitis and neuralgia. On April 24, 2017,
15 Patient 3 signed a Patient Medication Agreement which mandated medication be taken as
16 prescribed and stated that not following the agreement guidelines could result in discharge from
17 the practice. On April 24, 2017, Respondent began prescribing opiate medications to this patient,
18 including hydromorphone, fentanyl, and methadone.

19 44. Patient 3's medical chart did not document addressing the multiple inconsistent UDT
20 with Patient 3. For example, The UDT from April 24, 2017 was negative for hydromorphone,
21 although. CURES records show Patient 3 was receiving hydromorphone prescriptions in March
22 of 2017, from other providers.

23 45. Patient 3's CURES report shows hydromorphone was discontinued in July 2018, with
24 the last prescription being given June 13, 2018. The August 13, 2018, UDT was still positive for
25 hydromorphone.

26 46. The December 6, 2018, UDT was positive for hydromorphone, hydrocodone and
27 benzodiazepine metabolite. According to CURES, Respondent was prescribing only fentanyl and
28

1 methadone to Patient 3 in October and November 2018, and there is no indication any other
2 provider was prescribing these substances.

3 47. Respondent's overall care and treatment of Patient 3 constitutes unprofessional
4 conduct through repeated negligent acts and/or failure to maintain adequate and accurate medical
5 records for reasons including, but not limited, to the following:

6 a. Respondent did not address, and/or document addressing, the multiple inconsistent
7 UDTs over the course of treatment; and

8 b. Respondent did not document an assessment of substance abuse.

9
10 **FOURTH CAUSE FOR DISCIPLINE**

11 **(Unprofessional Conduct; and/or Repeated Negligent Acts; and/or Inadequate Medical
Record Keeping in the Care Provided to Patient 4, JB)**

12 48. Respondent Kareem Rashad Hubbard, M.D. is subject to disciplinary action under
13 sections 2234, 2234(c); and/or 2266 of the Code, regarding his treatment of Patient 4. The
14 circumstances are as follows:

15 49. Respondent's initial evaluation of Patient 4 was February 7, 2017, where he
16 diagnosed the patient with chronic pain, cervicalgia, cervical radiculopathy, low back pain,
17 arthropathy, and lumbar radiculopathy. Respondent took over prescribing for Patient 4 on March
18 15, 2017. Over the course of treatment, Respondent prescribed oxycodone, methadone,
19 dextroamphetamine sulfate, zolpidem, fentanyl, and morphine.

20 50. Patient 4's UDTs on April 7, 2017, November 3, 2017, January 5, 2018, were positive
21 for fentanyl. Respondent did not prescribe Patient 4 fentanyl. CURES for Patient 4 showed the
22 most recent fentanyl prescription, issued by another practitioner, was filled on December 14,
23 2016.

24 51. Patient 4's UDTs on June 9, 2017 and August 11, 2017 were positive for
25 hydrocodone. CURES for Patient 4, going back to November 2016, shows no hydrocodone
26 prescriptions.

27 52. Patient 4's UDT on October 12, 2018, was positive for fentanyl. CURES for Patient
28 4 showed the most recent fentanyl prescription was filled on May 8, 2018.

1 53. Patient 4's UDT on December 6, 2018, was positive for fentanyl. CURES for Patient
2 4 showed the most recent fentanyl prescription was filled on October 20, 2018, which was
3 prescribed by Respondent.

4 54. Respondent's overall care and treatment of Patient 4 constitutes unprofessional
5 conduct through and/or repeated negligent acts and/or failure to maintain adequate and accurate
6 medical records for reasons including, but not limited, to the following:

7 a. Respondent did not address, and/or document addressing, the multiple inconsistent
8 UDTs; and

9 b. Respondent did not address, and/or document addressing, a substance abuse history
10 over the course of treatment.

11 **FIFTH CAUSE FOR DISCIPLINE**

12 **(Unprofessional Conduct; and/or Repeated Negligent Acts; and/or Inadequate Medical**
13 **Record Keeping in the Care Provided to Patient 5, AA)**

14 55. Respondent Kareem Rashad Hubbard, M.D. is subject to disciplinary action under
15 sections 2234, 2234(c); and/or 2266 of the Code, regarding his treatment of Patient 5. The
16 circumstances are as follows:

17 56. Respondent initially evaluated Patient 5 on February 3, 2017. The diagnosis was
18 myalgia, cervical disc degeneration, cervicgia, cervical radiculopathy, low back pain, lumbar
19 radiculopathy, arthropathy, and sleep disorder. The diagnosis of long term current use of opiate
20 analgesic was added later.

21 57. Patient 5 signed a Patient Medication Agreement on September 29, 2017, indicating
22 that medications needed to be taken as prescribed, random drug testing would be conducted, and
23 failure to follow the medication agreement rules could result in discharge from the practice.
24 Respondent took over prescribing for Patient 5 on May 1, 2017. Over the course of treatment,
25 Respondent prescribed oxycodone, carisoprodol, and clonazepam.

26 58. Patient 5's UDT from July 18, 2017 was negative for clonazepam. CURES shows
27 Respondent prescribed 30-day supplies of clonazepam to Patient 5 on June 6, 2017 and July 8,
28 2017.

1 59. Patient 5's UDT from October 27, 2017, was negative for Soma. CURES shows
2 Respondent prescribed Patient 5 a 30-day supply of carisoprodol (Soma) on October 2, 2017.

3 60. Patient 5's UDT from July 13, 2018, was negative for aminoclonazepam and
4 meprobamate. CURES shows Respondent prescribed 30-day supplies of clonazepam to Patient 5
5 on June 26, 2018 and on July 12, 2018.

6 61. Patient 5's UDT from September 12, 2018 was negative for clonazepam. CURES
7 shows Respondent prescribed a 30-day supplies of clonazepam to Patient 5 on August 13, 2018
8 and on September 11, 2018.

9 62. Patient 5's UDT from November 9, 2018, was negative for clonazepam. CURES
10 shows Respondent prescribed 30-day supplies of clonazepam to Patient 5 on October 11, 2018
11 and on November 11, 2018.

12 63. Respondent's overall care and treatment of Patient 5 constitutes unprofessional
13 conduct through repeated negligent acts and/or failure to maintain adequate and accurate medical
14 records for reasons including, but not limited, to the following:

15 a. Respondent did not address, and/or document addressing, the multiple inconsistent
16 UDTs; and

17 b. Respondent did not address, and/or document addressing, a substance abuse history
18 over the course of treatment.

19 **SIXTH CAUSE FOR DISCIPLINE**

20 **(Unprofessional Conduct; and/or The Commission Of Any Act Involving Dishonesty;
21 and/or Action Or Conduct That Would Have Warrant Denial Of A Certificate; and/or
22 Disciplinary Action Taken By An Agency of the Federal Government for Any Act
Substantially Related to the Practice Regulated By the California License)**

23 64. Respondent Kareem Rashad Hubbard, M.D. is subject to disciplinary action under
24 sections 2234, 2234(e); 2234(f) and/or 2238 and/or 2261 and/or 141 of the Code. The
25 circumstances, are as follows:

26 65. The DEA began investigating Respondent in 2018 after receiving information that he
27 had prescribed large quantities of controlled substances. In early 2019, the DEA reviewed
28 Respondent's report from CURES and identified several red flags of abuse or diversion in

1 controlled substance prescribing, such as patients traveling long distances and receiving drug
2 cocktails, among other red flags.

3 66. On February 21, 2019, the DEA served an administrative subpoena on Respondent's
4 practice for his patient files and interviewed him regarding the care of some of the patients who
5 were the subject of the subpoena. Respondent was informed about several red flags of abuse or
6 diversion that the DEA identified in his controlled substance prescribing. Respondent
7 surrendered his DEA Certificate of Registration Control No. FH4334037 on February 21, 2019.

8 67. Two months later, on or about April 8, 2019, Respondent applied for a Drug
9 Enforcement Administration (DEA) Certificate of Registration as a practitioner in Schedules II
10 through V, with a proposed registered address in San Leandro. A DEA Diversion Investigator
11 (DI) was assigned to investigate Respondent's application for a license.

12 68. The application for a DEA license asked, "Has the applicant ever surrendered (for
13 cause) or had a federal controlled substance registration revoked, suspended, restricted or denied,
14 or is any such action pending?", to which the Respondent answered "No." The DEA determined
15 that Respondent's answer to this liability question was a material falsification.

16 69. The DEA also followed up on the prescribing issues, that prompted the surrender of
17 Respondent's prior DEA license, on four of Respondent's patients (patients LC, PB, SN, and JH).

18 70. The DEA retained an expert in the standard of care for prescribing controlled
19 substances in California. Following a hearing, the DEA found that the controlled substance
20 prescriptions issued by Respondent for Patients LC, PB, SN, and JH, between May 1, 2017, and
21 February 21, 2019, were issued without a legitimate medical purpose, were issued beneath the
22 standard of care for the practice of medicine in the State of California, and therefore outside of
23 the usual course of professional practice.

24 71. Respondent was denied a DEA Certificate of Registration based on a finding of
25 material falsification in his application and findings that that his care and treatment of four
26 patients fell beneath the standard of care for the practice of medicine in the State of California. A
27 copy of the DEA Decision and Order 2022-07702 is attached as Exhibit A.

28


1 72. Respondent's conduct and the action of the DEA, as detailed in Decision and Order
2 2022-07702, constitute cause for discipline pursuant to sections 2234, 2234(e); 2234(f) and/or
3 2238 and/or 2261 and/or 141 of the Code.

4 PRAYER

5 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
6 and that following the hearing, the Medical Board of California issue a decision:

- 7 1. Revoking or suspending Physician's and Surgeon's Certificate Number A 128252,
8 issued to Respondent Kareem Rashad Hubbard, M.D.;
- 9 2. Revoking, suspending or denying approval of Respondent Kareem Rashad Hubbard,
10 M.D.'s authority to supervise physician assistants and advanced practice nurses;
- 11 3. Ordering Respondent Kareem Rashad Hubbard, M.D., to pay the Board the costs of
12 the investigation and enforcement of this case, and if placed on probation, the costs of probation
13 monitoring; and
- 14 4. Taking such other and further action as deemed necessary and proper.

15
16 DATED: MAY 27 2022



WILLIAM PRASIFKA
Executive Director
Medical Board of California
Department of Consumer Affairs
State of California
Complainant

21 SF2021402477
22 43178645.docx
23
24
25
26
27
28

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

EXHIBIT A

DEA Decision and Order 2022-07702

controlled substance license, stating that "[a] registration under Section 303 to manufacture, distribute, or dispense a controlled substance . . . may be denied, refused renewal, suspended, or revoked by the Department of Financial and Professional Regulation." *Id.* at 570/304(a).

Here, the undisputed evidence in the record is that Registrant currently lacks authority to handle controlled substances in Illinois as his Illinois medical license is suspended and his Illinois controlled substance license is inoperative. As already discussed, a practitioner must hold a valid controlled substance license to dispense a controlled substance in Illinois. Thus, because Registrant lacks authority to handle controlled substances in Illinois, Registrant is not eligible to maintain a DEA registration. Accordingly, I order that Registrant's DEA registration be revoked.

Order

Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 824(a), I hereby revoke DEA Certificate of Registration No. BH5069205 issued to Kirk A. Hopkins, M.D. Further, pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 823(f), I hereby deny any pending application of Kirk A. Hopkins, M.D. to renew or modify this registration, as well as any other pending application of Kirk A. Hopkins, M.D. for additional registration in Illinois. This Order is effective May 11, 2022.

Anne Milgram,
Administrator

[FR Doc. 2022-07600 Filed 4-8-22; 8:48 am]
BILLING CODE 4410-08-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Kareem Hubbard, M.D.; Decision and Order

On June 4, 2020, the former Assistant Administrator, Diversion Control Division, Drug Enforcement Administration (hereinafter, DEA or Government), issued an Order to Show Cause (hereinafter, OSC) to Kareem Hubbard, M.D. (hereinafter, Applicant) of San Leandro, California. Request for Final Agency Action (hereinafter, RFAA) Exhibit (hereinafter RFAAX) 2 (OSC), at 1 and 12. The OSC proposed to deny Applicant's application for a DEA Certificate of Registration, as well as to deny any applications for any other registrations, pursuant to 21 U.S.C. 824(a)(1) and (4) because

Applicant "materially falsified [his] application" and because "[Applicant's] registration is inconsistent with the public interest, as that term is defined in 21 U.S.C. 823(f)." *Id.* at 1.

The OSC alleged that Applicant's application contained a materially false statement in which Applicant failed to disclose his previous surrender for cause of his DEA registration. *Id.* at 3. According to the OSC, Applicant had surrendered for cause his previous DEA registration "less than two months before submitting [his] application." *Id.* Further, the OSC alleged that Applicant "violated federal and California law by issuing prescriptions for controlled substances to four patients outside the usual course of professional practice and not for a legitimate medical purpose." *Id.* at 4.

The OSC notified Applicant of the right to request a hearing on the allegations or to submit a written statement, while waiving the right to a hearing, the procedures for electing each option, and the consequences for failing to elect either option. *Id.* at 11 (citing 21 CFR 1301.43). The OSC also notified Applicant of the opportunity to submit a corrective action plan. *Id.* at 11-12 (citing 21 U.S.C. 824(f)(2)(C)).

By letter dated July 23, 2020, Applicant requested a hearing through counsel. RFAAX 3 (Request for Hearing), at 1. In his Request for Hearing, Applicant requested that his application for DEA registration be granted, because "he applied for it in good faith and did not believe his surrender of [his] previous certificate was 'for cause.'" *Id.* Additionally, Applicant's Request for Hearing included an attachment addressing the Government's allegations in detail. *Id.* at 3-5. On July 23, 2020, Applicant also submitted a Corrective Action Plan in which he offered a "historical perspective, in addition to [his] interim practice activities and corrective action plan." RFAAX 4, at 5. On August 14, 2020, Applicant submitted a Withdrawal of Hearing Request in which he "with[drew] his request for a hearing in [the] matter" and "with[drew] his pending application for a new DEA Certificate of Registration."¹

¹ After an applicant has received an OSC regarding his or her application for DEA registration, the application may not be withdrawn without the permission of the Administrator. 21 CFR 1301.36(a). Here, Applicant had already received the OSC before attempting to withdraw his application, and he has not demonstrated good cause why his application should be withdrawn, nor do I find that withdrawal would be in the public interest due to the nature and extent of the allegations in front of me and the Applicant's stated intention that he will reapply for a registration. Adjudicating this matter to finality will create an

without "waiv[ing] his future right to reapply for [the] same." RFAAX 5, at 1; RFAAX 6 (Order Terminating Proceedings). On August 17, 2020, the Chief Administrative Law Judge John J. Mulrooney, II (hereinafter, the Chief ALJ) terminated the proceedings. RFAAX 6.

On September 23, 2020, the Government forwarded its RFAA, along with the evidentiary record for this matter, to my office. The Government seeks a final order of denial of Applicant's application for DEA registration because Applicant "materially falsified his application under 21 U.S.C. 824(a)(1), and committed acts which render his continued registration inconsistent with the public interest" under 21 U.S.C. 824(a)(4) and 823(f). RFAA, at 1. I issue this Decision and Order after considering the entire record before me, 21 CFR 1301.43(e), and I make the following findings of fact.

I. Findings of Fact

A. Application for DEA Registration

On or about April 8, 2019, Applicant applied for a DEA Certificate of Registration as a practitioner in Schedules II through V with a proposed registered address of 18035 E 14th St., San Leandro, CA 94578. RFAAX 1 (Certification of Non Registration), at 1. Applicant's application was assigned Control No. W19032408C and is in a "new pending" status. *Id.* On Applicant's application, when presented with the question, "Has the applicant ever surrendered (for cause) or had a federal controlled substance registration revoked, suspended, restricted or denied, or is any such action pending?" Applicant answered, "No." *Id.* Applicant previously held DEA Certificate of Registration Control No. FH4372859, which expired on October 31, 2016, and DEA Certificate of Registration Control No. FH4334937, which expired on October 31, 2019. *Id.* at 2. Both of Applicant's previous DEA

official record the Agency can use in any future interactions with Applicant. As additionally noted in *Olsen*, "a final adjudication is a public record of the Agency's expectations for current and prospective members of that community," and adjudications inform stakeholders, such as legislators and the public, about the Agency's work and allow them to provide feedback to the Agency, thereby helping shape how the Agency carries out its responsibilities under the CSA. *Id.* Adjudicating this matter to finality will create a public record to educate current and prospective registrants about the Agency's expectations regarding the responsibilities of registrants under the CSA and allow stakeholders to provide feedback regarding the Agency's enforcement priorities and practices. I have not permitted Applicant's application to be withdrawn. Accordingly, Applicant's withdrawal is not effective.

registrations are currently in a "retired" status. *Id.*

B. Investigation of Applicant

1. Declaration of Group Supervisor

According to a DEA Group Supervisor (hereinafter, the GS 1) in the San Jose Resident Office of the San Francisco Field Division assigned to investigate Applicant, "DEA began investigating [Applicant] in 2018 after receiving information that he had prescribed large quantities of controlled substances." RFAAX 8 (GS's Declaration), at 1. GS stated that in early 2019, "DEA reviewed [Applicant's] report from CURES, California's Prescription Data Monitoring Program" and "identified several red flags of abuse or diversion in [Applicant's] controlled substance prescribing, such as patients traveling long distances and receiving drug cocktails, among other red flags." *Id.* On February 21, 2019, DEA served an administrative subpoena on Applicant's practice for Applicant's patient files. *Id.* at 2; *see also id.* at Appendix (hereinafter, App.) A (administrative subpoena). On the same day, DEA also "interviewed [Applicant] regarding his care of some of the patients whose files were the subject of the administrative subpoena" and "informed [Applicant] about several red flags of abuse or diversion (such as long distances traveled by patients, high dosages, and opioid cocktails) that DEA identified in his controlled substance prescribing." *Id.* at 2. Accordingly, DEA asked Applicant to voluntarily surrender his DEA Certificate of Registration Control No. FH4334037, and he did. *Id.*; *see also id.* at App B (Applicant's signed surrender for cause).

2. Declaration of Diversion Investigator T.B.

A DEA Diversion Investigator (hereinafter, the DI) assigned to investigate Applicant's application found that Applicant voluntarily surrendered for cause his previous DEA Certificate of Registration Control No. FH4334037 on February 21, 2019. RFAAX 7 (DI's Declaration), at 2. The DI also found that Applicant "did not previously possess a DATA (Drug Addiction Treatment Act)[] Waiver number, which authorizes registrants to prescribe controlled substances for maintenance or detoxification treatment." *Id.*

Additionally, the DI obtained Applicant's 2017–2019 report from the CURES database to review Applicant's controlled substance prescribing from 2017–2019. *Id.* at 3; *see also id.* at App. B (CURES Report for Applicant dated

from May 1, 2017 to June 30, 2019). In response to administrative subpoenas served to various pharmacies, the DI obtained copies of the controlled substance prescriptions issued by Applicant to Patients L.C., P.B., S.N., and J.H. *Id.* at 3; *see also id.* at Apps. C–F (copies of patient prescription records). Further, the DI determined the respective distances between Applicant's previous registered address and the home addresses for Patients L.C., P.B., and S.N. by entering the addresses online into Bing Maps. *Id.* at 3; *see also id.* at App. G (printouts from Bing Maps). The DI found that the distance between Patient L.C.'s home address and Applicant's previous registered location was at least 30 miles; the distance between Patient P.B.'s home address and Applicant's previous registered location was nearly 80 miles; and the distance between Patient S.N.'s home address and Applicant's previous registered location was at least 35 miles. *Id.* at 4; *see also id.* at App. G (printouts from Bing Maps). Finally, in response to administrative subpoenas served to Applicant's practice, the DI obtained copies of the patient files for Patients L.C., P.B., S.N., and J.H. *Id.*; *see also id.* at Apps. H(i)–K (copies of patient files).

C. The Government Expert's Review of Applicant's Prescriptions

The DEA hired Dr. Timothy Munzing, M.D. to opine on Applicant's controlled substance prescribing based on the CURES report and the patient files described above. *Id.* at 4. Dr. Munzing is a physician licensed in California who has been the Family Medicine Residency Program Director at Kaiser Permanente Orange County for three decades. RFAAX 9 (Dr. Munzing's Declaration), at 1; *see also id.* at App. A (Dr. Munzing's CV). Dr. Munzing has also held an appointment as a full Clinical Professor at the University of California, Irvine School of Medicine since 2005 and has served on the Board of Directors of the Orange Academy of Family Physicians for over twenty years as well as on the Board of Directors for the California Academy of Family Physicians for five years. *Id.* Dr. Munzing currently serves on several other national and state boards and committees overseeing quality of care and residency and medical student training and in his three decades of practice has formally taught and/or lectured to thousands of physicians and students the core principles and guidelines of appropriate opioid and controlled substance medication prescribing. *Id.* at 1–2; *see also id.* at App. A. I find that Dr. Munzing is an expert in the standard of care for

prescribing controlled substances in California, and I give his report full credit.

Dr. Munzing was retained as an expert to determine whether or not Applicant's prescribing was "consistent with the usual course of professional practice, as required under 21 CFR 1306.04(a), and with California law." *Id.* at 2. Accordingly, Dr. Munzing's Declaration "explain[ed] [his] expert opinion on the standard of care in California for medical practice, particularly with respect to the prescribing of controlled substances; and [his] conclusions as to [Applicant's] prescribing outside of that standard of care with regard to specific prescriptions that [Applicant] issued to [the] four different patients" described above. *Id.*

1. The Standard of Care in California

Dr. Munzing attested that various state laws and regulations, as well as two guidelines published by the Medical Board of California, informed his opinion as to California's standard of care for the practice of medicine, particularly with respect to the prescribing of controlled substances for pain. *Id.* at 3–7. Dr. Munzing noted that California Health and Safety Code § 11153(a) requires that "[a] prescription for a controlled substance shall only be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his or her professional practice." *Id.* at 3. Further, California Health and Safety Code § 11154(a) states that "no person shall knowingly prescribe, administer, dispense, or furnish a controlled substance to or for any person . . . not under his or her treatment for a pathology or condition." *Id.* Dr. Munzing also cited California Business and Professions Code §§ 2242(a), 2234; and 725(a), noting that unprofessional conduct subject to sanction includes "[p]rescribing, dispensing, or furnishing [controlled substances] without an appropriate prior examination and a medical indication . . . [g]ross negligence"; "[r]epeated negligent acts"; "[i]ncompetence"; or "[t]he commission of any act involving dishonesty or corruption that is substantially related to the qualifications, functions, or duties of a physician and surgeon" . . . and "[r]epeated acts of clearly excessive prescribing, furnishing, dispensing, or administering of drugs . . ." *Id.* at 3–4. Finally, the two Medical Board of California guidelines referenced by Dr. Munzing included the Guide to the Laws Governing the Practice of

Medicine by Physicians and Surgeons² and the Guidelines for Prescribing Controlled Substances for Pain.³ *Id.* at 3.

Dr. Munzing opined that, as informed by the above statutes and guidelines, the California standard of care requires that before prescribing controlled substances, at minimum, a practitioner must:

- (1) "obtain a medical history and perform an appropriate physical examination";
- (2) "assess the patients' pain, physical and psychological functions, substance abuse history, and history of prior pain treatment (such as reviewing past medical records, laboratory studies, and imaging studies to establish a diagnosis and medical necessity)";
- (3) "assess any underlying or coexisting diseases or conditions and order and perform diagnostic testing if necessary";
- (4) "discuss the risks and benefits of using controlled substances and any other treatment modalities (such as non-opioid therapeutic options)";
- (5) "periodically review the course of pain treatment or gather any new information, if any, about the etiology of a patient's state of health";
- (6) "give special attention to patients who, by their own words and actions, pose a risk for medication misuse and/or diversion";
- (7) "maintain accurate and complete records"; and
- (8) "document the presence of a recognized medical indication for the use of a controlled substance."

Id. at 4. Additionally, Dr. Munzing opined that, as informed by guidelines from the Centers for Disease Control and Prevention (hereinafter, CDC)⁴ and from the Food and Drug Administration (hereinafter, FDA),⁵ the California standard of care imposes additional requirements and considerations for prescribing opioids as well as for prescribing benzodiazepines in combination with opioids. RFAAX 9, at 5–6. These additional requirements and considerations include that:

- (1) "[o]pioids prescribed at Morphine Milligram Equivalent ('MME') dosages above 90 mg per day significantly increase a patient's risk of overdose and death";

(2) practitioners must "carefully adjust, as well as closely monitor, patients who are prescribed MME dosages above 90 MME a day—a dangerously high dosage of opioids";

(3) "required monitoring when high-dosage opioids are prescribed include[s]: Periodic and close evaluations or examinations to determine the appropriateness of high-dosage opioids or [the consideration of] non-opioid alternatives; frequent and periodic review of a patient's report from [CURES]; and periodic urine drug screens";

(4) MME dosages above 90 mg per day should be avoided or carefully justified;

(5) "[t]he FDA requires 'Black Box' warnings about combining benzodiazepines with opioids" because "taking benzodiazepines with opioids can cause profound sedation, respiratory depression, coma, and death";

(6) "the combination of opioids and benzodiazepines should be avoided except in limited circumstances given the heightened risk of overdose and death when opioids and benzodiazepines are taken in combination";

(7) "[t]he combination of oxycodone, a benzodiazepine, and the muscle relaxant carisoprodol, is a dangerous drug cocktail known as the 'Holy Trinity'";

(8) "[t]he 'Holy Trinity' cocktail, as well as the combination of an opioid and a benzodiazepine, are both red flags of abuse or diversion"; and

(9) "[t]he 'Holy Trinity' cocktail, in particular, is a combination of drugs that is popular among the drug-abusing community."

Id. Finally, Dr. Munzing opined that the California standard of care requires "practitioners prescribing controlled substances to monitor and address red flags of abuse or diversion, such as long distances traveled, inconsistent urine drug screen results, early refills, and drug cocktails" and to "document how they addressed or resolved red flags of abuse or diversion." *Id.* at 6. Specifically, Dr. Munzing noted that, per the California standard of care:

(1) "[p]atients willing to travel long distances to see a physician to obtain controlled substances is a red flag of abuse or diversion" and physicians must address or resolve this red flag;

(2) "[p]eriodic urine drug screening is part of a physician's duty to perform ongoing monitoring of patients prescribed controlled substances" and physicians prescribing controlled substances must "address or resolve inconsistent urine drug screen results, which are red flags of abuse or diversion";

(3) "[i]nconsistent urine drug screen results that must be addressed or resolved are: (1) Positive results for non-prescribed controlled substances; and (2) negative results for prescribed controlled substances";

(4) "[e]ven should a physician address or resolve an inconsistent urine drug screen result," the physician must "proceed to closely monitor the patient, which may include additional and more frequent urine drug screens"; and

(5) "[p]atients with a history or pattern of obtaining or requesting early refills is a red

flag of abuse or diversion," and physicians must address or resolve this red flag;

Id. at 6–7.

Having read and analyzed all of the record evidence and law, I find that Dr. Munzing's declaration concerning a California physician's standard of care when prescribing controlled substances is supported by substantial evidence and is consistent with the explicit text of California law as well as state and federal guidelines. As such, I apply the standard of care of the state of California as described by Dr. Munzing.

2. The Subject Patients

i. Patient L.C.

From May 1, 2017, to February 21, 2019, and on an approximately monthly basis, Applicant prescribed Patient L.C. various opioids including oxycodone, hydrocodone-acetaminophen, Nucynta, Belbuca (buprenorphine), and hydromorphone, which Dr. Munzing calculated to amount to at least 420 mg MME per day. RFAAX 9, at 8; *see also* RFAAX 7, App. B (Applicant's CURES Report), App. C (prescription records for Patient L.C.), and App. H(i)–(ii) (patient file for Patient L.C.). Based upon his review of Patient L.C.'s file, Dr. Munzing concluded that Applicant "prescribed such high-dosage opioids without consistently performing detailed examinations or evaluations, dependably considering non-opioid alternatives, or reliably weaning Patient L.C. off such high dosages." RFAAX 9, at 8. In particular, "[Applicant's] frequent concurrent prescribing for Patient L.C. of oxycodone and hydrocodone-acetaminophen (both short-acting opioids) was therapeutically duplicative and therefore medically unnecessary." *Id.* Dr. Munzing also stated that, "[t]here was no medical justification for [Applicant's] Belbuca (buprenorphine) prescriptions for Patient L.C." and noted that "[Applicant] could not have prescribed Belbuca (a Schedule III opioid) for maintenance or detoxification treatment (for which Belbuca is usually prescribed) because [Applicant] did not possess a DATA-waiver at the time he issued these prescriptions." *Id.* Moreover, according to Dr. Munzing, "given all the other high-dosage opioids Patient L.C. was prescribed, there was no legitimate medical purpose for additionally prescribing buprenorphine for pain management." *Id.*

Additionally, Dr. Munzing concluded, based upon his review of Patient L.C.'s file, that "[Applicant] frequently prescribed to Patient L.C. either (1) a combination of opioids and the

² Available at: <http://web.archive.org/web/20210823182242/http://www.mbc.ca.gov/Download/Documents/laws-guide.pdf>.

³ Available at: <https://www.mbc.ca.gov/Download/Publications/pain-guidelines.pdf>.

⁴ The CDC guidelines referenced by Dr. Munzing included the CDC publication, "Calculating Total Daily Dose of Opioids for Safer Dosage" and the CDC's "Guideline for Prescribing Opioids for Chronic Pain" published in 2016. *Id.* at 5; *see* https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf and <https://www.cdc.gov/drugoverdose/prescribing/guideline.html>.

⁵ Dr. Munzing referenced the FDA publication, "New Safety Measures Announced for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepines" published in 2016. RFAAX 9, at 5–6; *see* <https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm518150.htm>.

benzodiazepine, clonazepam . . . or (2) the 'Holy Trinity' cocktail, which consists of an opioid; a benzodiazepine, such as clonazepam; and carisoprodol . . . without performing adequate evaluation or monitoring to medically justify these combinations." *Id.* at 8–9. Specifically, Dr. Munzing noted that by February 8, 2018, Patient L.C. reported experiencing "side effects attributable to [Applicant's] controlled substance prescriptions and which [Applicant] did not adequately examine or evaluate." *Id.* at 9. Further, "[Applicant] improperly continued to prescribe these dangerous drug cocktails after February 6, 2018[,] without further examining or evaluating Patient L.C.'s reported side effects." *Id.*

Finally, Dr. Munzing concluded, based upon his review of Patient L.C.'s file, that Applicant failed to address several red flags of abuse or diversion. *Id.* First, Dr. Munzing noted that there was no documentation that Applicant adequately addressed or resolved Patient L.C.'s inconsistent urine drug screen results, which included positive results for controlled substances that Applicant had not prescribed to Patient L.C. and that Patient L.C. had not filled the prescriptions anywhere in California according to CURES reports, some of which were dangerous in combination with the high-dosage opioids that Applicant had prescribed to Patient L.C. *Id.* at 9–10. Patient L.C.'s urine drug screen results also included negative results for controlled substances for which Applicant had issued prescriptions to Patient L.C. and which Patient L.C. had filled. *Id.* at 10. Second, Dr. Munzing noted that there was no documentation that Applicant adequately addressed or resolved evidence of Patient L.C.'s early refills of controlled substances on at least 34 occasions between 2017 and 2019.⁶ *Id.* at 10–11. Finally, Dr. Munzing noted that there was no documentation that Applicant addressed or resolved evidence that Patient L.C. traveled a long distance (at least 80 miles roundtrip from Martinez, CA to Applicant's office in San Leandro, CA) to obtain controlled substances from Applicant on a nearly monthly basis. *Id.*; see also RFAAX 7, App. G (printouts from Bing Maps), at 3.

⁶Dr. Munzing noted that "[e]ven though [Applicant] documented on several occasions about providing early refills due to Patient L.C. claiming to have lost her tablets from vomiting, there was no legitimate medical purpose for consistently continuing to provide early refills for this reason without first treating Patient L.C.'s issues with vomiting." *Id.* at 11.

ii. Patient P.B.

On an approximately monthly basis, Applicant prescribed Patient P.B. various opioids including OxyContin, oxycodone, Nucynta, and levorphanol tartrate, which Dr. Munzing calculated to amount to at least 840 mg MME per day. RFAAX 9, at 11; see also RFAAX 7, App. B (Applicant's CURES Report), App. D (prescription records for Patient P.B.), and App. I (patient file for Patient P.B.). Based upon his review of Patient P.B.'s file, Dr. Munzing concluded that Applicant "prescribed such high-dosage opioids without consistently performing detailed examinations or evaluations, dependably considering non-opioid alternatives, or reliably weaning Patient P.B. off such high dosages." RFAAX 9, at 11–12. In particular, Dr. Munzing stated that, "[Applicant's] concurrent prescribing for Patient P.B. of oxycodone and Nucynta (both short-acting opioids) on at least one occasion was therapeutically duplicative and therefore medically unnecessary." *Id.* at 12. Additionally, Dr. Munzing concluded, based upon his review of Patient P.B.'s file, that "[Applicant] frequently prescribed to Patient P.B. either (1) a combination of opioids and the benzodiazepine, clonazepam . . . or (2) the 'Holy Trinity' cocktail, which consists of an opioid; a benzodiazepine, such as clonazepam; and carisoprodol . . . without performing adequate evaluation or monitoring to medically justify these combinations." *Id.*

Finally, Dr. Munzing concluded, based upon his review of Patient P.B.'s file, that Applicant failed to address several red flags of abuse or diversion. *Id.* Specifically, Dr. Munzing noted that there was no documentation that Applicant adequately addressed or resolved Patient P.B.'s inconsistent urine drug screen results, which included positive results for controlled substances that Applicant had not prescribed to Patient P.B. and for which Patient P.B. had not filled the prescriptions anywhere in California according to CURES reports. *Id.* at 12–13. Patient P.B.'s inconsistent urine drug screen results also included a negative result for a controlled substance for which Applicant had issued prescriptions to Patient P.B. and which Patient P.B. had filled. *Id.* at 13. Dr. Munzing also noted that there was no documentation that Applicant addressed or resolved evidence that Patient P.B. traveled a long distance (at least 160 miles roundtrip from Newman, CA to Applicant's office in San Leandro, CA) to obtain controlled substances from Applicant on a nearly monthly

basis. *Id.* at 14; see also RFAAX 7, App. G (printouts from Bing Maps), at 4.

iii. Patient S.N.

On an approximately monthly basis, Applicant prescribed Patient S.N. various opioids including OxyContin, oxycodone, and Xtampza, which Dr. Munzing calculated to amount to at least 406 mg and 885 mg MME per day. RFAAX 9, at 14; see also RFAAX 7, App. B (Applicant's CURES Report), App. E (prescription records for Patient S.N.), and App. J (patient file for Patient S.N.). Based upon his review of Patient S.N.'s file, Dr. Munzing concluded that Applicant "prescribed such high-dosage opioids without consistently performing detailed examinations or evaluations, dependably considering non-opioid alternatives, or reliably weaning Patient S.N. off such high dosages." RFAAX 9, at 14.

Additionally, Dr. Munzing concluded, based upon his review of Patient S.N.'s file, that Applicant failed to address several red flags of abuse or diversion. *Id.* First, Dr. Munzing noted that there was no documentation that Applicant adequately addressed or resolved Patient S.N.'s inconsistent urine drug screen results, which included a positive result for controlled substances that Applicant had not prescribed to Patient S.N. and for which Patient S.N. had not filled the prescriptions anywhere in California according to CURES reports. *Id.* Dr. Munzing also noted that "[Applicant] failed to document any test results for Patient S.N.'s three subsequent urine drug screens performed in 2018." *Id.* at 14–15. Second, Dr. Munzing noted that there was no documentation that Applicant adequately addressed or resolved evidence of Patient S.N.'s early refills of controlled substances on at least three occasions between 2017 and 2019. *Id.* at 15. Finally, Dr. Munzing noted that there was no documentation that Applicant addressed or resolved evidence that Patient S.N. traveled a long distance (at least 70 miles roundtrip from Pittsburg, CA to Applicant's office in San Leandro, CA) to obtain controlled substances from Applicant on a nearly monthly basis. *Id.*; see also RFAAX 7, App. G (printouts from Bing Maps), at 1–2.

iv. Patient J.H.

On an approximately monthly basis, Applicant prescribed Patient J.H. various opioids including oxycodone, oxycodone-acetaminophen, OxyContin, and fentanyl, which Dr. Munzing calculated to amount to at least 1,350 mg MME per day. RFAAX 9, at 15; see also RFAAX 7, App. B (Applicant's

CURES Report), App. F (prescription records for Patient J.H.), and App. K (patient file for Patient J.H.). Based upon his review of Patient J.H.'s file, Dr. Munzing concluded that Applicant "prescribed such high-dosage opioids without consistently performing detailed examinations or evaluations, dependably considering non-opioid alternatives, or reliably weaning Patient J.H. off such high dosages." RFAAX 9, at 15. In particular, "[Applicant's] frequent concurrent prescribing for Patient J.H. of oxycodone and oxycodone-acetaminophen (both short-acting opioids) was therapeutically duplicative and therefore medically unnecessary." *Id.*

Dr. Munzing also concluded, based upon his review of Patient J.H.'s file, that "[Applicant] frequently prescribed Patient J.H. the 'Holy Trinity' cocktail, which consists of an opioid; a benzodiazepine, such as alprazolam . . . and carisoprodol . . . without performing adequate evaluation or monitoring to medically justify this combination." *Id.* at 15–16. Specifically, Dr. Munzing noted that by January 29, 2018, Patient J.H. reported having experienced "side effects attributable to [Applicant's] controlled substance prescriptions and which [Applicant] did not adequately examine or evaluate." *Id.* at 16. Further, "[Applicant] improperly continued to prescribe the 'Holy Trinity' after January 29, 2018[,] without further examining or evaluating Patient J.H.'s reported side effects." *Id.* Dr. Munzing also concluded, based upon his review of Patient J.H.'s file, that, "[Applicant] frequently prescribed stimulants, either amphetamine salts . . . or modafinil . . . without any legitimate medical purpose." *Id.* Dr. Munzing noted that he did not find any apparent medical diagnosis or evaluation in Patient J.H.'s file for Attention-Deficit Hyperactivity Disorder (ADHD), "for which amphetamine salts are normally used to treat." *Id.* Additionally, Dr. Munzing noted that "while amphetamine salts and modafinil can be used to treat drowsiness or extreme sleepiness, the use of such stimulants for Patient J.H. was not medically appropriate as the patient's drowsiness or sleepiness were likely side effects of his prescribed high-dosage opioids." *Id.*

Finally, Dr. Munzing concluded, based upon his review of Patient J.H.'s file, that Applicant failed to address or resolve several red flags of abuse or diversion. *Id.* Specifically, Dr. Munzing noted that there was no documentation that Applicant adequately addressed or resolved Patient J.H.'s inconsistent urine drug screen results, which included positive results for controlled

substances that Applicant had not prescribed to Patient J.H. and for which Patient J.H. had not filled the prescriptions anywhere in California according to CURES reports, some of which were dangerous in combination with the high-dosage opioids that Applicant had prescribed to Patient J.H. *Id.* at 16–17. Applicant's inconsistent urine drug screen results also included positive results for alcohol, which Dr. Munzing noted can "amplify the risk of overdose and death associated with the 'Holy Trinity' cocktail [Applicant] prescribed Patient J.H." *Id.* at 17. Moreover, Applicant's inconsistent urine drug screen results included negative results for controlled substances for which Applicant had issued prescriptions to Patient J.H. and which Patient J.H. had filled. *Id.* at 17–18.

Based on his expert medical opinion, Dr. Munzing concluded, and I agree, that "the controlled substance[] prescriptions issued by [Applicant] for Patients L.C., P.B., S.N., and J.H. between May 1, 2017, and February 21, 2019[,] were issued without a legitimate medical purpose and were issued beneath the standard of care for the practice of medicine in the State of California, and therefore outside of the usual course of professional practice." *Id.* at 7.

II. Discussion

A. Government's Position

In its RFAA, the Government sought denial of Applicant's application for DEA registration because Applicant "materially falsified his application under 21 U.S.C. 824(a)(1), and committed acts which render [granting his] registration inconsistent with the public interest." RFAA, at 1 (citing 21 U.S.C. 824(a)(1), (a)(4) and 823(f)). Specifically, the Government argued that Applicant had materially falsified his application when he falsely provided a "No" response to the liability question asking him whether he had ever surrendered for cause a federal controlled substance registration and when he knew or should have known that his "No" response was false. *Id.* at 19. The Government also argued that Applicant had repeatedly violated state and federal law by issuing prescriptions for controlled substances to four patients outside of the standard of care in the State of California and outside of the usual course of professional practice. *Id.* at 21. The Government concluded its RFAA by requesting that Applicant's application for DEA registration be denied and that any

applications by Applicant for any other registrations be denied. *Id.* at 25.

B. Applicant's Position

Within his Request for Hearing and his Corrective Action Plan, both submitted in response to the OSC, Applicant offered explanation as to his misconduct, however, Applicant did not offer supporting evidence nor any ability for me to assess the credibility of his unsworn statements.⁷ See RFAAX 3 (Request for Hearing) and RFAAX 4 (Corrective Action Plan). In his Request for Hearing, Applicant addressed the allegations of material falsification and stated that when, on February 21, 2019, DEA investigators visited Applicant's registered location to serve an administrative subpoena for patient files from his practice, the investigators "explained that the DEA was concerned about certain red flags associated with [his] controlled substance prescribing, including but not limited to, long distances traveled by patients, high dosages, and drug cocktails." RFAAX 3, at 3. Applicant stated that he "believed that if [he] surrendered [his] DEA certificate that [he] would be demonstrating good faith that [he] had done nothing wrong." *Id.* Applicant also stated that he "was unaware and did not understand that [he] was being asked to surrender [his] DEA certificate 'for cause.'" *Id.*

In both his Request for Hearing and his Corrective Action Plan, Applicant offered a "historical perspective" regarding the improper prescribing allegations. RFAAX 3, at 3–5; RFAAX 4, at 5. According to Applicant, in 2018, he "acquired a medical practice from anesthesiologist/pain medicine specialist [M. J.], a frequent prescriber of schedule II and III medications." RFAAX 4, at 5. Applicant stated that prior to considering the purchase of M. J.'s practice, and before working with him, Applicant "discussed with him his patient population" and "[a] contract was drawn up ensuring that all [M. J.] was doing was within state and deferral [sic] laws." RFAAX 3, at 3. Applicant stated that he and M. J. agreed that M. J. would continue to work with Applicant for the first year and then turn the practice over to Applicant. *Id.* The contract was signed by both

⁷ Applicant specifically did not opt to submit a written statement in lieu of a hearing under 21 CFR 1316.49. In this case, I have considered these unsworn submissions minimally to represent Applicant's position because they address the underlying allegations. Even if I afforded those unsupported and unsworn statements the weight of a written statement, they would be insufficient to rebut the Government's case for denial of Applicant's application for the reasons stated herein.

Applicant and M. J. and witnessed by a third party. *Id.* According to Applicant, CDC guidelines were also discussed, and M. J. "informed [Applicant] that [they] were recommendations, not mandates." *Id.* M. J. said that patients had been established with him for 20–30 years. *Id.* Further, M. J. discussed the "tolerance displayed by long term chronic pain patients," their "functionality" (that patients could "go to work, address activities of daily life, [and] enjoy the benefits of being sociable") and "an overall high level of productivity of patients." *Id.* M. J. further stated that "if there had been any problems, he would not [have been] allowed to operate for all this time, incident free." *Id.*

According to Applicant, upon his evaluation of the patients, he realized that "many patients were not getting the proper workups, diagnostic studies[,] and referrals needed to improve their pain." *Id.* Further, "[m]any of them were exhibiting chronic pain due to lack of early appropriate treatment" and "patients had been pushed toward interventional procedures that either were not indicated or ended up hurting them." *Id.* Applicant stated that "[t]his was all done under the guise of performing a 'trial'" and that "[m]edications had been escalated due to failed 'trials' and recommended due to inability to control pain with interventions." *Id.* Applicant stated that "[a]s medications were elevated and encouraged by [M. J.], patients had become dependent on their current regimens, and had been educated that their pain was so severe that high medication dosages were indicated." *Id.*

According to Applicant, in April 2019, he was the victim of a cyber crime when ransomware was placed onto his servers and corrupted all of his electronic medical records. *Id.* at 4. Applicant stated that "[a]lthough no HIPAA violation occurred and the charts were retrieved on an external hard drive, upon attempting to upload the data, the external hard drive became corrupted leading to loss of all charting information." *Id.* As a result of the data loss, Applicant was only able to provide management details for the four patients referenced in the OSC by memory and not by specific references to their patient records. *Id.* Applicant stated that "[a]ll four patients cited in the [OSC] were patients managed or at one time managed by [M. J.]." *Id.* Further, "[n]one of them were naïve to opioids and were elevated to the regimens in question by [M. J.]." *Id.* Applicant concluded that "[a]ll of these patients, from the moment [he] inherited them, were already and

for years [had been] above the current state, federal[,] and CDC guidelines." *Id.*

Regarding Patient L.C., Applicant stated that her medications had been escalated prior to her becoming Applicant's patient. *Id.* According to Applicant, Patient L.C. had indicated that "she had tried many procedures for her condition including [] a trial of a Spinal Cord Stimulator (SCS)." *Id.* However, Patient L.C. said that during the SCS trial she had been hurt and she "frequently had her mother [with her] at appointments to advocate that she would never have [an] SCS [again] due to the adverse experience during the trial." *Id.* Applicant stated that he and other physicians believed that Patient L.C. was getting too much medication and Applicant "used [other] opinions to further bolster [his own]," but Patient L.C. disagreed and "cited [M. J.]." *Id.* Applicant then started Patient L.C. on a "slow wean" of her medications. *Id.* According to Applicant, Patient L.C. was also undergoing a trial of Belbuca for her pain, and as he was weaning down her medications, Belbuca was used "to continue to cover her chronic pain." *Id.* Applicant stated that Belbuca "is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate." *Id.* For Patient L.C., Belbuca was "not being used for maintenance or detoxification treatment." *Id.*

Regarding Patient P.B., Applicant stated that her medications had been escalated prior to her becoming Applicant's patient. *Id.* According to Applicant, there had been no diagnostic studies on file for Patient P.B. and weaning down of her medications occurred once diagnostic studies were performed. *Id.*

Regarding Patient S.N., Applicant stated that his medications had also been escalated prior to him becoming Applicant's patient. *Id.* at 5. According to Applicant, Patient S.N. "cited tailbone pain that made sitting for long periods difficult" and "had a job where he often traveled by plane and was not able to stop and take breaks from sitting." *Id.* "Refills made early usually represented a documented trip he had on behalf of his profession." *Id.* According to Applicant, Patient S.N. "had never been worked up for his pain" and "[m]ultiple diagnostic studies were conducted in attempts to find a solution." *Id.* Applicant stated that he started Patient S.N. on a weaning down of his medication and "[a]fter S.N. transferred care to obtain medication from another provider, he continued to work with [Applicant] in an attempt to

solve his pain." *Id.* Applicant also stated that Patient S.N. "attempted a nerve block to further investigate a solution to his pain, though no opioids were being prescribed by [Applicant] at the time." *Id.*

Finally, regarding Patient J.H., Applicant stated that his medications too had been escalated prior to him becoming Applicant's patient. *Id.* According to Applicant, Patient J.H. had sustained an occupational injury and was being managed under a workers' compensation insurer. *Id.* Patient J.H. previously had a failed surgical procedure and was a candidate for a revision procedure. *Id.* Applicant stated that he had agreed with the revision procedure as an option, but that the procedure was denied by the insurer. *Id.* According to Applicant, "[o]ther non-opioid options were recommended to help decrease [Patient J.H.'s use of] opioids and [to] manage his pain." *Id.*

Applicant concluded his Request for Hearing by asserting that his patients "had been taught that issues that could have normally been mitigated by appropriate treatment were instead only able to be addressed with high levels of medication" and that "[t]he belief had been ingrained that medications were the only option." *Id.* Applicant asserted that his patients in turn became dependent on their medications and that "[a]s a competent, caring doctor, [he] could not abandon them." *Id.* Applicant stated that he "was working diligently to reduce their medication use, but found a number of patients who had been on long term opiate use" and thus "[had] to very slowly wean them." *Id.*

In his Corrective Action Plan, Applicant stated, "Given my training in physical medicine and rehabilitation, my focus was to taper his patients from high dose opioids and offer them an array of alternative treatment options," RFAAX 4, at 5. According to Applicant, "[o]n February 23, 2019, in the midst of this process, DEA officers presented to the clinic and requested that [he] surrender [his] DEA license" to which Applicant "voluntarily complied." *Id.* Applicant further stated that "[a]t that time, patients who were on scheduled medications were provided the option of tapering off their medications or provided a list of alternative physicians for transfer of care, including an addiction medicine specialist." *Id.* Applicant asserted that "[f]or those patients who decided to taper/ discontinue their medications, [he] continued to provide them care in the framework of holistic treatment options such as physical and behavioral therapies, procedures, durable medical

equipment, self-directed exercise, and other non-medical pain management strategies." *Id.*

Applicant stated that he "proceeded to close the practice, and after full disclosure, [he has] been evaluating and treating patients at RehabOne Medical Group, Inc." *Id.* Applicant chose to work at RehabOne "because of their positive reputation in the community [and] their focus on functional restoration." *Id.* Applicant also chose RehabOne for "their attentiveness to documentation, record keeping, and compliance [as well as] medical provider supervision[,] oversight, and collaboration." Finally, Applicant chose RehabOne for their "adherence with evidence-based guideline recommendations for prescribing controlled substances." *Id.* Applicant stated that "[a]lthough [he has] not personally prescribed any scheduled medications, RehabOne has a strong risk management policy that utilizes opioid and addiction risk screening tools, long-term controlled substance agreements, routine CURES analysis, initial and random urine toxicology, and '5 As' monitoring." *Id.* Further, "[w]hen opioid or non-opioid medications are considered appropriate as part of a treatment plan, all efforts are made to utilize the lowest dose and frequency possible to achieve optimal outcomes," *Id.* According to Applicant, "[a]t RehabOne, medications are very carefully considered as part of an overall, comprehensive treatment strategy with the primary goal of functional restoration and quality of living." *Id.*

Applicant concluded his Corrective Action Plan by stating that "[m]oving forward, [he plans] to strictly adhere to these practices and principles as [he strives] to help [his] patients lead full and meaningful lives." *Id.* Applicant stated that he "will continue to review and implement the most current evidence-based guidelines for the treatment of chronic pain" and requested that "[DEA] reinstate [his] DEA license so that [he] can utilize appropriate medications as one tool in the toolbox to achieve these outcomes." *Id.*

C. Analysis

1. 21 U.S.C. 823(f): The Five Public Interest Factors

Pursuant to section 303(f) of the Controlled Substances Act (hereinafter, CSA), "[t]he Attorney General shall register practitioners . . . to dispense . . . controlled substances . . . if the applicant is authorized to dispense . . . controlled substances under the laws of

the State in which he practices." 21 U.S.C. 823(f). Section 303(f) further provides that an application for a practitioner's registration may be denied upon a determination that "the issuance of such registration . . . would be inconsistent with the public interest." *Id.* In making the public interest determination, the CSA requires consideration of the following factors:

- (1) The recommendation of the appropriate State licensing board or professional disciplinary authority.
- (2) The applicant's experience in dispensing, or conducting research with respect to controlled substances.
- (3) The applicant's conviction record under Federal or State laws relating to the manufacture, distribution, or dispensing of controlled substances.
- (4) Compliance with applicable State, Federal, or local laws relating to controlled substances.
- (5) Such other conduct which may threaten the public health and safety.

21 U.S.C. 823(f).

The DEA considers these public interest factors in the disjunctive. *Robert A. Leslie, M.D.*, 68 FR 15227, 15230 (2003). Each factor is weighed on a case-by-case basis. *Moxall v. Drug Enf't Admin.*, 412 F.3d 165, 173-74 (D.C. Cir. 2005). Any one factor, or combination of factors, may be decisive. *David H. Gilks, M.D.*, 58 FR 37507, 37508 (1993). Thus, there is no need to enter findings on each of the factors. *Hoxie v. Drug Enf't Admin.*, 419 F.3d 477, 482 (6th Cir. 2005). Furthermore, there is no requirement to consider a factor in any given level of detail. *Trawick v. Drug Enf't Admin.*, 861 F.2d 72, 76-77 (4th Cir. 1988). The balancing of the public interest factors "is not a contest in which score is kept; the Agency is not required to mechanically count up the factors and determine how many favor the Government and how many favor the registrant. Rather, it is an inquiry which focuses on protecting the public interest . . ." *Jayam Krishna-Iyer, M.D.*, 74 FR 459, 462 (2009). When deciding whether registration is in the public interest, the DEA must consider the totality of the circumstances. *See generally Joseph Gaudio, M.D.*, 74 FR 10083, 10094-95 (2009) (basing sanction on all evidence on record).

The Government does not dispute that Applicant holds a valid state medical license and is authorized to dispense controlled substances in the State of California where he practices. *See RFAAX 2 (OSC)*, at 2. While I have considered all of the public interest factors⁸ in 21 U.S.C. 823(f), the

⁸ As to Factor One, there is no record evidence of disciplinary action against Applicant's state medical license. 21 U.S.C. 823(f)(1). State authority

Government's evidence in support of its *prima facie* case for denial of Applicant's application is confined to Factors Two and Four. *See RFAAX*, at 18-25. Moreover, the Government has the burden of proof in this proceeding. 21 CFR 1301.44. I find that the Government's evidence satisfies its *prima facie* burden of showing that Applicant's registration would be "inconsistent with the public interest," 21 U.S.C. 824(f). I further find that Applicant failed to provide sufficient evidence to rebut the Government's *prima facie* case.

i. Factors Two and Four

Evidence is considered under Public Interest Factors Two and Four when it reflects compliance (or non-compliance) with laws related to controlled substances and experience dispensing controlled substances. Established violations of the CSA, DEA regulations, or other laws regulating controlled substances at the state or local level are cognizable when considering whether granting a registration is consistent with the public interest.

Here, the Government has alleged that from at least May 1, 2017, through at least February 21, 2019, Applicant unlawfully issued prescriptions for controlled substances in violation of the CSA. RFAAX 2 (OSC), at 2 and 4-10. Specifically, the Government alleges that Applicant repeatedly violated 21 CFR 1306.4(a) by issuing prescriptions for controlled substances to Patients L.C., P.B., S.N., and J.H. beneath the standard of care and outside the usual course of professional practice in California—the state in which Applicant is applying for DEA registration. *Id.*

to practice medicine is "a necessary, but not a sufficient condition for registration . . ." *Robert A. Leslie, M.D.*, 68 FR at 15230. Therefore, "[t]he fact that the record contains no evidence of a recommendation by a state licensing board does not weigh for or against a determination as to whether continuation of [or granting of a] DEA certification is consistent with the public interest." *Roni Drexler, M.D.*, 75 FR 19434, 19444 (2011).

As to Factor Three, there is no evidence in the record that Applicant has been convicted of an offense under either federal or state law "relating to the manufacture, distribution, or dispensing of controlled substances." 21 U.S.C. 823(f)(3). However, as Agency cases have noted, there are a number of reasons why a person who has engaged in criminal misconduct may never have been convicted of an offense under this factor, let alone prosecuted for one. *Dewey C. Mackay, M.D.*, 75 FR 49856, 49873 (2010). Agency cases have therefore found that "the absence of such a conviction is of considerably less consequence in the public interest inquiry" and is therefore not dispositive. *Id.*

As to Factor Five, the Government's evidence fits squarely within the parameters of Factors Two and Four and does not raise "other conduct which may threaten the public health and safety." 21 U.S.C. 823(f)(5). Accordingly, Factor Five does not weigh for or against Applicant.

According to the CSA's implementing regulations, a lawful controlled substance order or prescription is one that is "issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his professional practice." 21 CFR 1306.04(a). The Supreme Court has stated, in the context of the CSA's requirement that schedule II controlled substances may be dispensed only by written prescription, that "the prescription requirement . . . ensures patients use controlled substances under the supervision of a doctor so as to prevent addiction and recreational abuse . . . [and] also bars doctors from peddling to patients who crave the drugs for those prohibited uses." *Gonzales v. Oregon*, 546 U.S. 243, 274 (2006).

I found above that the Government's expert credibly declared, as supported by California law and federal and state guidelines, that the standard of care in California requires physicians to, among other things, perform a sufficient physical exam and take a medical history, counsel patients on the risks and benefits of the use of particular controlled substances, periodically review the course of treatment and adjust as needed, give special attention to patients who pose a risk for medication misuse and diversion, and monitor and address any red flags of abuse or diversion. Further, the standard of care in California requires additional care and consideration for the prescribing of opioids, as well as for the prescribing of benzodiazepines in combination with opioids.

Based on the credible and un rebutted opinion of the Government's expert, I found above that Applicant issued a high number of controlled substance prescriptions to at least four different patients, often for extremely high doses of opioids and in dangerous combinations of opioids and benzodiazepines, without performing detailed examinations or evaluations, dependably considering non-opioid alternatives, reliably warning patients off such high dosages, or resolving or documenting resolution of red flags of abuse and/or diversion as required by the standard of care. *See supra* I.C.2.i-iv. My findings demonstrate that Applicant repeatedly violated the applicable standard of care when prescribing controlled substances and that his conduct was not an isolated occurrence, but occurred with multiple patients. *See Kaniz Khan Jaffery*, 85 FR 45667, 45685 (2020); *Wesley Pope, M.D.*, 82 FR 42981, 42986 (2017). As such, I find that the Government has presented substantial evidence that from May 1,

2017, to February 21, 2019, Applicant issued controlled substance prescriptions to the four subject patients beneath the applicable standard of care in California and outside the usual course of professional practice. Accordingly, I am sustaining the Government's allegation that Applicant violated 21 CFR 1306.04(a).

The Government has also alleged that Applicant's prescribing practices in regard to the subject patients violated California State law. RFAAX 2, at 2-3 and 4-10. Echoing the federal regulations, California law requires that a "prescription for a controlled substance shall only be issued for a medical purpose by an individual practitioner acting in the usual course of his or her professional practice." Cal. Health & Safety Code § 11153(a).⁹ Further, California Business and Professions Code § 2242(a) states, "Prescribing, dispensing, or furnishing [controlled substances] without an appropriate prior examination and a medical indication[] constitutes unprofessional conduct." ¹⁰ Accordingly, I find that, similarly to 21 CFR 1306.04(a), the record contains substantial evidence that Applicant violated these provisions with respect to the controlled substance prescriptions for Patients L.C., P.B., S.N., and J.H.

In sum, I find that the record contains substantial evidence that Applicant issued a multitude of prescriptions for controlled substances, including high dosages of opioids, to multiple patients beneath the applicable standard of care, outside the usual course of professional practice, and in violation of federal and state law. I, therefore, find that Factors

⁹The Government also alleged that Applicant violated California Health and Safety Code § 11154(a), which states that "no person shall knowingly prescribe, administer, dispense, or furnish a controlled substance to or for any person . . . not under his or her treatment for a pathology or condition." Dr. Munzing's expert report did not address whether Applicant knowingly prescribed controlled substances to or for any person not under his treatment for a pathology or condition. Accordingly, I find that the Government has not met its burden to prove by substantial evidence that Applicant violated California Health and Safety Code § 11154(a).

¹⁰The Government also alleged that Applicant violated California Business and Professions Code §§ 2234 and 726(a), which state that unprofessional conduct includes "[i]gross negligence"; "[r]epeated negligent acts"; "[i]ncompetence"; or "[t]he commission of any act involving dishonesty or corruption that is substantially related to the qualifications, functions, or duties of a physician and surgeon" as well as "[r]epeated acts of clearly excessive prescribing, furnishing, dispensing, or administering of drugs." Dr. Munzing's expert report did not address whether Applicant engaged in these particular forms of unprofessional conduct. Accordingly, I find that the Government has not met its burden to prove by substantial evidence that Applicant violated California Business and Professions Code §§ 2234 and 726(a).

Two and Four weigh in favor of denial of Applicant's application and thus find Applicant's registration to be inconsistent with the public interest in balancing the factors of 21 U.S.C. 823(f).

2. 21 U.S.C. 824(a)(1): Material Falsification

In addition to the public interest allegations, as previously mentioned, the OSC in this matter also alleges that Applicant's application for registration should be denied, because Applicant's application contains a materially false response to a liability question. RFAAX 2, at 1 and 3-4; *see supra* I.A-B.1. The CSA, however, places the provision addressing the ramification of a material falsification with the bases for revocation or suspension of a registration. 21 U.S.C. 824(a). Prior Agency decisions have addressed whether it is appropriate to consider a material falsification and other provisions of 21 U.S.C. 824(a) when determining whether or not to grant a practitioner registration application. For over forty-five years, Agency decisions have concluded that it is. *See, e.g., Lisa M. Jones, N.P.*, 86 FR 52196 (2021), *Robert Wayne Locklear*, 86 FR 33738 (2021) (collecting Agency decisions). These decisions offer multiple bases and analyses for that conclusion. 86 FR at 33744-45.

Having read and analyzed all of the record evidence, I find from clear, unequivocal, convincing, and un rebutted record evidence that Applicant surrendered (for cause) his previous DEA registration on February 21, 2019. *See supra* I.A-B.1. Having read and analyzed all of the record evidence, I find from clear, unequivocal, convincing, and un rebutted record evidence that when presented with the liability question, "Has the applicant ever surrendered (for cause) or had a federal controlled substance registration revoked, suspended, restricted or denied, or is any such action pending?"—Applicant answered, "No." *Id.* Applicant's false answer to this liability question in his application implicates two of the public interest factors that the CSA requires me to consider (*see supra* II.C.1): Applicant's experience in dispensing controlled substances and Applicant's compliance with applicable federal laws relating to controlled substances. 21 U.S.C. 823(f)(2) and (4); *Frank Joseph Stirlacci, M.D.*, 85 FR 45229, 45234 (2020). As such, Applicant's false response to this liability question in his application was "predictably capable of affecting, i.e., had a natural tendency to affect" my official decision on Applicant's application. *Frank Joseph Stirlacci*,

M.D., 85 FR at 45238. Accordingly, I find from clear, unequivocal, convincing, and un rebutted record evidence that Applicant's application for DEA registration contains a material falsification, which is an independent basis for the denial of Applicant's application.

III. Sanction

The Government has established grounds to deny a registration; therefore, I will review any evidence and argument that Applicant submitted to determine whether or not Applicant has presented "sufficient mitigating evidence to assure the Administrator that [he] can be trusted with the responsibility carried by such a registration." *Samuel S. Jackson, D.D.S.*, 72 FR 23848, 23853 (2007) (quoting *Leo R. Miller, M.D.*, 53 FR 21931, 21932 (1988)). "Moreover, because 'past performance is the best predictor of future performance,' *ALRA Labs, Inc. v. Drug Enf't Admin.*, 54 F.3d 450, 452 (7th Cir. 1995), [the Agency] has repeatedly held that where a registrant has committed acts inconsistent with the public interest, the registrant must accept responsibility for [the registrant's] actions and demonstrate that [registrant] will not engage in future misconduct.'" *Jayam Krishna-Iyer*, 74 FR 459, 463 (2009) (quoting *Medicine Shoppe*, 73 FR 364, 367 (2008)); see also *Samuel S. Jackson, D.D.S.*, 72 FR at 23853; *John H. Kennedy, M.D.*, 71 FR 35705, 35709 (2006); *Prince George Daniels, D.D.S.*, 60 FR 62884, 62887 (1995). The issue of trust is necessarily a fact-dependent determination based on the circumstances presented by the individual respondent; therefore, the Agency looks at factors, such as the acceptance of responsibility and the credibility of that acceptance as it relates to the probability of repeat violations or behavior and the nature of the misconduct that forms the basis for sanction, while also considering the Agency's interest in deterring similar acts. See *Arvinder Singh, M.D.*, 81 FR 8247, 8248 (2016).

A. Acceptance of Responsibility

As previously discussed, although Applicant initially requested a hearing and submitted a Corrective Action Plan on July 23, 2020, Applicant later withdrew his hearing request on August 14, 2020, and the proceedings were terminated. See RFAAX 3 (Request for Hearing); RFAAX 4 (Corrective Action Plan); RFAAX 5 (Withdrawal of Hearing Request); RFAAX 6 (Order Terminating Proceedings). As such, there is no credible, sworn evidence on the record regarding acceptance of responsibility

for me to consider. Further, even if I could consider the explanations that Applicant offered in his Initial Request for Hearing and Corrective Action Plan, they do not demonstrate sufficient acceptance of responsibility or evidence of remedial measures that would aid me in entrusting Applicant with registration. See RFAAX 3 and RFAAX 4.

As to the allegations of material falsification, Applicant claimed that, at the time he surrendered his DEA certificate for cause, he misunderstood that he was doing so and believed instead that he was "demonstrating good faith that [he] had done nothing wrong."¹¹ RFAAX 3, at 3. Whether or not Applicant's claims are truthful, they do not demonstrate acceptance of responsibility for his (intentional or not) materially false response to a liability question. Rather, Applicant's claims demonstrate an attempt to either shift the blame to DEA investigators for failing to properly explain the situation to him or to simply use his ignorance as an excuse, neither of which inspire confidence that Applicant fully appreciates an applicant's obligation to provide truthful and accurate responses on an application for DEA registration.

As to the allegations of improper prescribing, Applicant claimed that he had inherited the subject patients from his purchase of another physician's practice and that the physician he had purchased the practice from had assured him that all was proper regarding the practice and his patients. RFAAX 3, at 3; RFAAX 4, at 5. However, Applicant claimed that he only later realized that all was not proper regarding the practice and the patients that he had inherited and that he had done the best that he could to wean the four subject patients off of their high dosages of controlled substances. RFAAX 3, at 3–5; RFAAX 4, at 5. Again, Applicant's statements do not demonstrate acceptance of responsibility for his improper prescribing, but instead demonstrate an attempt to shift the blame to the physician whom he had inherited the subject patients from or, at the very least, a failure to acknowledge that, regardless of his intentions, his prescribing was beneath the applicable standard of care and outside the usual course of professional practice.

As for remedial measures, I do not consider them when an Applicant has

¹¹ It is noted that in spite of Applicant's claims that he did not know that he was surrendering his previous registration "for cause," RFAAX 3, at 3, the DEA Form 104 that Applicant signed was clearly entitled, "Surrender for Cause of DEA Certificate of Registration," RFAAX 6, App. B (emphasis added).

not unequivocally accepted responsibility, however, even if I were to consider Applicant's remedial measures here, I do not find them to be sufficient. Applicant discussed how since surrendering his DEA registration, he has closed his practice and has begun treating patients at another practice, one which he lauds for its adherence to best practices for prescribing controlled substances. RFAAX 4, at 5. Applicant also stated his own commitment to adhering to these best practices moving forward, however, Applicant did not specify in what ways he would ensure this adherence. *Id.* As such, Applicant has not sufficiently demonstrated that he is ready to be entrusted with the responsibility of registration.

B. Specific and General Deterrence

In addition to acceptance of responsibility, the Agency considers both specific and general deterrence when determining an appropriate sanction. *Daniel A. Glick, D.D.S.*, 80 FR 74,800, 74,810 (2015). Specific deterrence is the DEA's interest in ensuring that a registrant complies with the laws and regulations governing controlled substances in the future. *Id.* General deterrence concerns the DEA's responsibility to deter conduct similar to the proven allegations against the registrant for the protection of the public at large. *Id.* In this case, I believe that denial of Applicant's application for DEA registration would deter Applicant and the general registrant community from the improper prescribing of controlled substances as well as from ignoring their obligation to provide accurate and truthful responses on an application for DEA registration.

C. Egregiousness

The Agency also looks to the egregiousness and the extent of the misconduct as significant factors in determining the appropriate sanction. *Garrett Howard Smith, M.D.*, 83 FR at 18,910 (collecting cases). Here, the record contains substantial evidence that Applicant issued a high number of prescriptions for controlled substances, including high dosages of opioids and dangerous combinations of opioids and benzodiazepines, to at least four different patients beneath the applicable standard of care and outside the usual course of professional practice. Further, Applicant gave a materially false response to a liability question on his application for DEA registration that directly concerned his improper prescribing practices and his negative history with DEA registration.

As discussed above, to be granted a registration when grounds for denial

exist, an Applicant must convince the Administrator that his acceptance of responsibility is sufficiently credible to ensure that his misconduct will not reoccur and that he can be entrusted with registration. I find that Applicant has not met this burden. In sum, Applicant has not offered any credible evidence on the record to rebut the Government's case for denial of his application and Applicant has not demonstrated that he can be entrusted with the responsibility of registration. Accordingly, I will order the denial of Applicant's application below.

Order

Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 823(f) and 21 U.S.C. 824(a), I hereby deny the pending application for a Certificate of Registration, Control Number W19032408C, submitted by Kareem Hubbard, M.D., as well as any other pending application of Kareem Hubbard, M.D. for additional registration in California. This Order is effective May 11, 2022.

Anne Milgram,
Administrator.

[FR Doc. 2022-07702 Filed 4-8-22; 8:45 am]
BILLING CODE 4410-08-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration [Docket No. 20-17]

Noah David, P.A.; Decision and Order

On March 9, 2020, a former Assistant Administrator, Diversion Control Division, of the Drug Enforcement Administration (hereinafter, DEA or Government), issued an Order to Show Cause (hereinafter, OSC) to Noah David, P.A. (hereinafter, Respondent) of Richmond, Virginia. Administrative Law Judge Exhibit (hereinafter, ALJX) 1 (OSC), at 1. The OSC proposed the revocation of Respondent's DEA Certificate of Registration No. MD3130717 (hereinafter, COR or registration) and the denial of "any pending application for renewal or modification of such registration and any applications for any other DEA registrations, pursuant to 21 U.S.C. 824(a)(4), because [Respondent's] registration is inconsistent with the public interest, as that term is defined in 21 U.S.C. 823(f)." *Id.*

On April 7, 2020, the Respondent timely requested a hearing, which commenced (and ended) on September 22, 2020, at the DEA Hearing Facility in Arlington, Virginia with the parties,

counsel, and witnesses participating via video teleconference (VTC). On December 8, 2020, Chief Administrative Law Judge John J. Mulrooney, II (hereinafter, the Chief ALJ) issued his Recommended Rulings, Findings of Fact, Conclusions of Law and Decision of the Administrative Law Judge (hereinafter, Recommended Decision or RD). By letter dated January 5, 2021, the ALJ certified and transmitted the record to me for final Agency action. In that letter, the ALJ advised that neither party filed exceptions. Having reviewed the entire record, I adopt the ALJ's rulings, findings of fact, as modified, conclusions of law and recommended sanction with minor modifications, where noted herein. *A

Recommended Rulings, Findings of Fact, Conclusions of Law, and Decision of the Administrative Law Judge

John J. Mulrooney, II

Chief Administrative Law Judge

December 8, 2020

*B After carefully considering the testimony elicited at the hearing, the admitted exhibits, the arguments of counsel, and the record as a whole, I have set forth my recommended findings of fact and conclusions of law below.

I. Findings of Fact

A. Allegations

The Government alleges that the Respondent's COR should be revoked because he has committed acts which render his continued registration against the public interest. ALJX 1, at 1. Specifically, the Government contends that on numerous occasions between April 2014 and November 2018, the Respondent unlawfully prescribed controlled substances to his wife without establishing a *bona fide* practitioner-patient relationship and without properly documenting treatment. *Id.* at 3-4. The Government additionally alleges that the Respondent conspired with colleagues to unlawfully receive controlled substances. *Id.* at 4.

*A I have made minor modifications to the RD. I have substituted initials or titles for the names of witnesses and patients to protect their privacy and I have made minor, nonsubstantive, grammatical changes and nonsubstantive, conforming edits. Where I have made substantive changes, omitted language for brevity or relevance, or where I have added to or modified the ALJ's opinion, I have noted the edits with an asterisk, and I have included specific descriptions of the modifications in brackets following the asterisk or in footnotes marked with a letter and an asterisk. Within those brackets and footnotes, the use of the personal pronoun "I" refers to myself—the Administrator.

*B I have omitted the RD's discussion of the procedural history to avoid repetition with my introduction.

B. Stipulations

The parties entered into a robust set of factual stipulations which were accepted by the tribunal. Accordingly, the following factual matters are deemed conclusively established in this case:

1. The Respondent is registered with the DEA as a practitioner to handle controlled substances in Schedules II-V under DEA COR No. MD3130717 at 5211 West Broad Street, Suite 101, Richmond, Virginia 23230-3000.

2. DEA COR No. MD3130717 was issued on May 15, 2019 and expires by its own terms on June 30, 2022.

3. The Respondent is presently licensed as a physician assistant in Virginia under License No. 0110004605, which expires April 30, 2021.

4. Respondent Exhibit 1 is a true and correct copy of the Respondent's COR.

5. The Respondent prescribed the following controlled substances on the following dates to his wife, B.D.:

- (1) 11/28/2018: Oxycodone-Acetaminophen 5-325, 36 tablets
- (2) 11/20/2018: Oxycodone-Acetaminophen 5-325, 36 tablets
- (3) 11/08/2018: Oxycodone-Acetaminophen 5-325, 36 tablets
- (4) 10/30/2018: Oxycodone-Acetaminophen 5-325, 36 tablets
- (5) 10/01/2018: Oxycodone-Acetaminophen 10-325, 18 tablets
- (6) 9/21/2018: Oxycodone-Acetaminophen 10-325, 18 tablets
- (7) 9/13/2018: Oxycodone-Acetaminophen 10-325, 18 tablets
- (8) 9/06/2018: Oxycodone-Acetaminophen 5-325, 60 tablets
- (9) 8/22/2018: Oxycodone-Acetaminophen 5-325, 60 tablets
- (10) 8/17/2018: Oxycodone-Acetaminophen 5-325, 60 tablets
- (11) 7/23/2018: Oxycodone-Acetaminophen 5-325, 42 tablets
- (12) 7/10/2018: Oxycodone-Acetaminophen 5-325, 84 tablets
- (13) 7/03/2018: Oxycodone-Acetaminophen 10-325, 18 tablets
- (14) 5/30/2018: Acetaminophen-Codaine #3, 60 tablets
- (15) 5/30/2018: Acetaminophen-Codaine #3, 60 tablets (refill)
- (16) 5/30/2018: Acetaminophen-Codaine #3, 60 tablets (refill)
- (17) 5/21/2018: Oxycodone-Acetaminophen 5-325, 12 tablets
- (18) 5/08/2018: Diazepam 5mg, 30 tablets
- (19) 4/24/2018: Oxycodone-Acetaminophen 10-325, 28 tablets
- (20) 3/18/2018: Oxycodone-Acetaminophen 10-325, 28 tablets
- (21) 2/15/2018: Oxycodone-Acetaminophen 10-325, 28 tablets
- (22) 2/09/2018: Oxycodone-Acetaminophen 10-325, 12 tablets
- (23) 1/23/2018: Oxycodone-Acetaminophen 10-325, 28 tablets
- (24) 1/19/2018: Oxycodone-Acetaminophen 10-325, 12 tablets
- (25) 1/05/2018: Oxycodone-Acetaminophen